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CIRCADIAN REGULATION OF mTOR SIGNALING PATHWAY VIA BMAL1 
DEPENDENT MECHANISM 
ROHINI VISHAL KHAPRE 
ABSTRACT 
Understanding mechanisms of aging is important for the treatment and prevention 
of age-associated pathologies. However, these mechanisms are not well 
understood. Recently we have demonstrated that the circadian clock (an internal 
time keeping system) regulates longevity in mammals, but the molecular 
mechanisms are not known. The aim of our current study is to investigate a 
possible interconnection between the circadian clock and mTORC1 (mammalian 
target of Rapamycin) signaling pathway. mTORC1 pathway is a nutrient response 
pathway involved in many cellular processes; many recent studies indicate a role 
of mTORC1 pathway in aging. Here we demonstrate that circadian system 
regulates mTORC1 signaling in vivo. Analysis of liver, heart and spleen from WT 
mice reveals circadian rhythms in phosphorylation of known mTOR targets such 
as S6K1 and 4EBPs. These rhythms are disrupted in the tissues of BMAL1 KO 
mice providing potential mechanistic explanation of reduced longevity of these 
mice. Further analysis of expression of mTORC1 complex components and 
upstream regulators demonstrated that some of them have circadian rhythms at 
protein and mRNA levels. Taken together, these results suggest that circadian 
ix 
 
clock controls aging by regulating mTOR signaling pathway through BMAL1 
dependent control of gene expression. 
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CHAPTER I 
INTRODUCTION 
 
1.1 The circadian clock 
Earth’s rotation around its axis creates certain environmental changes with 
a periodicity of approximately 24 hr. Light and dark cycles are one of the most 
prominent changes which occur approximately every 24 hours. If organisms can 
keep track of time and anticipate these changes, they can adapt their physiology 
and behavior to the optimal phase of light and dark cycle. This adaptation can 
impart survival advantage to organisms (1, 2, 3). For this purpose, many organisms 
have developed an endogenous time keeping system or device known as the 
circadian clock (Circa = around, Diem = day). The circadian clock is found in almost 
all organisms from prokaryotes to eukaryotes. It is represented by an 
autoregulatory feedback loop of genes generating circadian rhythms in 
physiological processes (1,4). From Cynobacteria to mammals, several core 
circadian clock genes responsible for creating circadin rhythms have been 
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identified. Even though the core circadian genes are not conserved among 
species, the basic mechanism to create rhythms is conserved. The core circadian 
clock proteins form an autoregulatory negative feedback loop which works with a 
periodicity of 24 hr. BMAL1 is a transcription factor and a core component of the 
mammalian circadian clock. BMAL1 heterodimerizes with another core clock 
component, CLOCK and binds to E-box elements in the promoter region of target 
genes to their drive expression (5). 
Previously, our lab has demonstrated that Bmal1 deficiency results in 
premature aging and age related pathologies in mice. In this work we proposed 
that BMAL1 is an important regulator of oxidative stress and Bmal1 deficiency can 
lead to Stress -induced senescence in vivo, which might contribute to premature 
aging observed in Bmal1-/- mice. In agreement with previously published data, we 
observed that Bmal1-/- mice show significantly higher accumulation of senescent 
cells in vivo in comparison with WT. We reported that Bmal1 deficiency results in 
increased sensitivity to oxidative stress and Stress -induced senescence. We also 
investigated the role of circadian clock in mTORC1 signaling pathway. mTORC1 
signaling pathway is an evolutionarily conserved nutrient sensing pathway 
involved in various cellular processes, metabolism and aging. It is activated by 
nutrients and growth factors. Since nutrients availability depends on organisms 
feeding rhythms, which are regulated by the circadian clock, we proposed a link 
between the circadian clock and mTORC1 pathway. We demonstrated that the 
circadian clock negatively regulates the mTORC1 pathway and disruption of the 
3 
circadian clock in BMAL1 deficient mice results in increased mTORC1 signaling, 
which might contribute to premature aging. 
1.2 Characteristics of circadian clock 
The circadian clock demonstrates certain characteristics that help to confer 
selective advantage to organisms. 
 It generates rhythms in metabolism and behavior with a periodicity of 24 
hours.  
 These rhythms are persistent even in the absence of external cues such as 
light. (in constant darkness) 
  Circadian clock can be entrained by external stimuli such as light and food 
which helps organisms to adapt to environmental changes. 
 Circadian rhythms are genetically determined. 
In general, the circadian clock system can be illustrated by 3 interconnected 
components, 
1) Input pathway, which receives external cues and transmits them 
2) Clock unit, which creates rhythms 
3) Downstream pathways, which exhibit these rhythms. 
The circadian clock serves to synchronize different biochemical and 
physiological processes which help many organisms to separate incompatible 
biochemical reactions. Underlying the importance of circadian clock, circadian 
rhythms are found at all cellular organization levels. 
4 
1.3 Functional organization of circadian clock in mammals. 
According to the current model, the mammalian circadian clock is organized 
in hierarchical manner, with master clock or central oscillator located in the 
Suprachiasmatic Nucleus (SCN) of hypothalamus region in the brain. Many 
peripheral clocks exist in different tissues, which are synchronized by the master 
clock. The SCN is a small collection of around 20000-100000 neurons (in 
mammals) which receives photic information from retina through Retino-
Hypothalamic Tract (RHT). Neurons in SCN show robust circadian rhythms in 
electrical activity and gene expression. The mechanisms of synchronization of 
master clock in SCN and peripheral clocks are not clear. However, some studies 
show that SCN produces humoral and chemical signals that synchronizes 
peripheral clocks with the environment (Figure1). According to published 
microarray data, 10% of genes in different tissues are under circadian clock 
control, which result in rhythmic changes in physiology and behavior. 
  
2 
                          
Figure 1 : Functional organization of the mammalian circadian clock 
In mammals master clock is situated in SCN (SupraChiasmatic Nucleus) of 
hypothalamic region of brain. It is entrained by light signals received from retina 
(eye). SCN creates signals to synchronize peripheral clocks from various tissues 
to environment. Peripheral clocks create rhythms in various physiological 
processes. 
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1.4 Molecular Components of circadian clock 
Circadian rhythms are genetically determined and many genes have been 
identified as a part of the circadian clock. Even though the circadian clock proteins 
are not conserved among organisms, at molecular level the circadian clock is 
organized with similar design principles of period, amplitude and phase. It is 
represented by two interconnected transcription-translation feedback loops. 
In mammalian cells, circadian clock oscillations are accomplished by 
interconnecting auto regulatory feedback loops in which specific clock proteins 
repress their own transcription and also generate oscillations in transcription of 
many genes, which are not part of the circadian clock loop. These genes are 
responsible for producing rhythmicity in processes and behavior (1, 7). Various 
proteins that comprise the mammalian circadian clock are BMAL1 (Brain Muscle 
Arnt such as 1) and CLOCK (Circadian Locomotor Output Cycles Kaput), three 
PERIOD proteins (PER1, PER2, PER3), 2 Cryptochromes (CRY1, CRY2) (7). 
BMAL1 and CLOCK are transcription factors and share three characteristic regions 
involved in their function: one BHLH (basic Helix- Loop- Helix) region and two PAS 
(Per-Arnt-Sim) region required for DNA binding and heterodimerization (Figure 2). 
BMAL1 and CLOCK heterodimerize in the cytoplasm and the complex translocate 
to the nucleus, where it binds to E box elements in the promoter region of various 
genes to drive their transcription. PERIODs and CRYs form the so called positive 
arm of autoregulatory loop (1, 7). PERIOD has three mammalian homologs Per1, 
Per2, Per3, containing 2 PAS domains (PAS A and PAS B) involved in PER-PER 
interactions and CRY binding domain involved in binding with CRYs. In mammals 
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there are two CRY homologs which are involved in BMAL1: CLOCK repression. 
PERIODs and CRYs accumulate in the cytoplasm and bind to each other to form 
heterodimers. These heterodimers translocate back to the nucleus and repress 
their own transcription by negatively regulating the BMAL1: CLOCK complex, thus 
forming the negative arm of the loop (1, 7 8, 9) (Figure 3). 
Another autoregulatory loop for circadian clock is represented by Dec1 and Dec2 
(differentially expressed in Chondrocytes) which are bHLH transcription factors. 
BMAL1: CLOCK complex drives their expression by binding to E-box elements in 
the promoter region. In feedback, DECs exert a repressing effect on BMAL1: 
CLOCK induced transactivation of target genes. Two mechanisms have been 
proposed in their repressing effect: one by physical binding with Bmal1 through 
bHLH region and second DECs compete with BMAL1: CLOCK complex for binding 
to E-box elements in promoter region of target genes (1, 8, 10). 
The third auto regulatory loop is represented by REV-ERBs and RORα 
proteins regulating expression of Bmal1. Rev-ERB and ROR proteins belong to 
retinoic acid-related orphan receptor (ROR) with DNA binding domain recognizing 
ROR elements (A(A/T)NT(A/G)GGTCA) REV-ERBα and RORα compete with 
each other for binding to ROR elements in Bmal1 promoter region. REV-ERBα 
acts as a negative regulator while RORα acts as a positive regulator of Bmal1 
transcription (1, 8, 11, 12, 13). 
In addition to various interconnected autoregulatory loops, additional 
mechanisms supplement regulation and complexity to circadian clock maintaining 
Circadian rhythms. Some of these mechanisms include post-transcriptional 
5 
modifications, post-translational modifications, chromatin remodeling and stability 
of Clock proteins and intracellular localization (7). 
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Figure 2 : Functional domains of the mammalian BMAL1 and CLOCK 
proteins 
bHLH: basic Helix loop helix, NLS: Nuclear localization Signal, NES: Nuclear 
Export Signal, PAS:PER-ARNT-SIM, CKI: Casein kinase I, MAPK: Mitogen 
activated protein kinase, Poly Q: Poly glutamine motif. This figure is adapted from 
http://www.sciencedirect.com/science/article/pii/S0959437X05001292                 
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Figure 3 : The positive and negative transcriptional–translational feedback 
loops controlling the circadian machinery. 
BMAL1 and CLOCK proteins form heterodimer complex and drive the expression 
of the target genes  Pers ,  Crys ,  Decs ,  Rev-Erbα  , and  Rors  through binding 
to the circadian E-box elements in their promoter region. Upon translation, PERs 
and CRYs accumulate in the cytoplasm and form a complex which inhibits the 
BMAL1: CLOCK complex transcriptional activity, and hence their own expression 
forming autoregulatory negative feedback loop. The nuclear receptor REV-ERB α 
represses BMAL1 expression and the retinoid-related orphan receptor ROR 
promotes the transcription of BMAL1 through binding to ROR elements in the 
Bmal1 promoter. DEC proteins compete with the BMAL1: CLOCK complex for their 
8 
own E box located in the DEC promoter and so inhibit their own transcription. The 
BMAL1: CLOCK complex also regulates the expression of various clock-controlled 
genes (CCGs), which play important roles in many physiological functions. This 
figure is adapted from Khapre et al. Ann Med. 2010 Sep; 42(6):404-15. 
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1.5 Disruption of the circadian clock and human health 
As the circadian clock regulates various physiological processes, disruption 
of the circadian clock has an evident effect on physiological processing, disease 
related pathways and overall well-being of organisms (14, 15). Detailed knowledge 
about genetic basis of the circadian clock and availability of various model 
organisms for disrupted circadian clock has linked numerous neurological, 
cardiovascular and metabolic disorders (8, 14, 15). 
The sleep- wake cycle is regulated by the circadian clock. The disruption of 
clock also affects the sleep-wake cycle leading to Circadian Rhythm Sleep 
Disorders. (CRSD). Some disorders commonly found in humans are Delayed 
Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS) and 
Non-24 advanced sleep syndrome (non-24). Recently, mutations in the human 
circadian gene per2 and ck1δ have been shown to result in Familial Advanced 
Sleep Phase Syndrome (FASPS) in humans. In this syndrome, patients exhibit 
early sleep onset and early awakening. In DSPS, sleep and wake patterns are 
delayed significantly compared with conventional times and have been linked to 
mutations in the per3 gene, whereas individuals with non-24 show 1 hour delay in 
sleep onset and wake up times every day (17, 18). 
Disruption of the circadian clock can affect mood related disorders.  
Seasonal Affective Disorder (SAD) is one of the mood disorder characterized by 
depressive symptoms during winter. It is related to desynchronization of 
environmental and internal body rhythms. Light therapy has been used efficiently 
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to treat patients with SAD. For individuals with mood disorders, strict daily routines 
of meal and bed time are beneficial (18). 
Many studies have shown that specific mutations of different clock genes 
show specific behavioral abnormality. Mutation in clock gene results in behavior 
indicative of mania in bipolar disorder in humans. Mice mutant for per genes show 
preference for abusive drugs such as cocaine and alcohol (2, 16). It is known that 
poor sleep health is related to neuronal disorders. With increased incidences of 
neurodegenerative disorders such as Alzheimer’s disease and Huntington’s 
disease, research for association of disrupted  circadian clock has been started 
recently (2,17). 
Approximately 15 % Americans work as shift workers. This rotating work 
can desynchronize circadian clock at the molecular level in central (SCN) as well 
as peripheral oscillators and their coordination (16, 18). Mood disorders have also 
been observed in shift workers. Several studies with night and rotating shift 
workers have been done. 
Many acute and long term studies with shift workers show alternations in 
carbohydrate and lipid metabolism, growth hormone and glucocorticoid secretion 
and insulin resistance. Frequency and severity of cardiovascular problems such 
as hypertension, coronary heart disease, and myocardial infarction is increased in 
shift workers (8, 16). An increased risk of various cancers such as breast, colon 
and prostate have been associated with shift work, rapid translocation over time 
zones and jet lag (1, 16). 
11 
1.6 Circadian clock and aging 
The purpose of all the studies is to improve and extend human lifespan. 
However, the question of what controls human lifespan has remain unanswered. 
To answer this, even though many theories of Aging have been proposed, there is 
no agreement on this issue. Aging can be considered as either a risk factor for 
diseases or a consequence of the development of diseases. At molecular level it 
is represented by a decline in overall fitness and well-being of organism driven by 
deterioration of systems involved in homeostatic mechanisms (1, 19, 20, 21). With 
progressing age, circadian oscillations deteriorate with reduction in amplitude. In 
humans, changes in sleep-wake cycles, hormone rhythms and other behavioral 
cycles have been described with aging (1, 22). However, in recent years, it has 
been observed that the circadian clock can equally affect aging and development 
of many pathological conditions associated with aging. 
Development of various models, especially flies and mice with deficiency of 
different core clock components, has provided a great tool to study the connection 
between circadian clock and aging (1). Manipulation in light and dark periods 
resulted in 10% reduction in lifespan of wild type Drosophila melanogaster (flies). 
Another study with mutations in core clock proteins demonstrated reduced 
longevity in flies. Flies with mutation in period genes showed 15% reduced lifespan 
compared with WT flies (19, 23). 
1.7 Mouse models for disrupted circadian clock and aging 
A considerable amount of work has been done on molecular mechanisms 
of the circadian clock. The mammalian circadian clock has been extensively 
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studied in mouse models. Experimental models with targeted disruption of core 
clock genes have added significant input to the knowledge of their circadian and 
non-circadian function (19). The core  circadian clock mutants lose circadian 
rhythms in gene expression, however the expression levels of many genes change 
in different ways with each circadian mutant showing unique pattern of clock and 
clock controlled gene expression, therefore the phenotype for each clock mutant 
is different (19,20). 
1.7.1 Bmal1-/- mice 
Bmal1-/- mice gives the most severe phenotype among all circadian clock 
proteins. Bmal1 deficiency results in complete loss of circadian rhythms in gene 
expression and activity (1, 20, 19). 
Our lab is working with Bmal1-/- mice. The most prominent phenotype 
observed in this mice is a premature aging. Previously, our lab has reported that 
Bmal1-/- mice are indistinguishable from WT littermates at birth but start to show 
signs of growth retardation and premature aging at 16-18 weeks of age (4-5 
months).  At age of 35-40 weeks, Bmal1-/- mice look like aged mice (6, 19, and 
20). The average lifespan of Bmal1 deficient mice is 37.0 + 12.1 weeks while 
average life span of WT mice with same background is approximately 120 weeks 
(6). 
Along with reduced lifespan, Bmal1-/- mice also display many age related 
pathological conditions as follows: 
 Reduced organ weight (kidney, spleen) 
13 
 Sarcopenia (reduced muscle mass associated with decrease number of 
muscle fibers and their diameter) 
 Osteoporosis (reduced bone mass and composition) 
 Reduced visceral and subcutaneous adipose tissue 
 Decreased hair growth 
 Development of cataract 
 Chronic cornea inflammation 
 Changes in blood cell composition 
 Ectopic calcification of tendons and cartilage 
 Male and female infertility 
Data published from our lab and different groups indicate that Bmal1 plays a 
significant role in normal tissue homeostasis (19, 20, 21, 22, and 23). The 
molecular mechanisms involved in premature aging in Bmal1 deficient mice are 
not known. Our lab is working to identify these mechanisms and one of the 
potential mechanism suggested was regulation of ROS (reactive oxygen species) 
homeostasis. Bmal1 deficient mice displayed increased accumulation of ROS in 
the tissues (heart, kidney and spleen), which also demonstrated age dependent 
reduction in size. Our lab demonstrated that treatment with antioxidant N-acetyl-L-
cysteine to Bmal1 deficient mice through their entire lifespan significantly 
increased average and maximum life span in mice. It also reduced certain age 
related pathologies such as cataract and weight loss but had no effect on many 
other age related pathologies observed in Bmal1 deficient mice. This indicated that 
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oxidative stress by ROS can affect aging but other ROS independent mechanisms 
might be also involved (21). 
1.7.2 Period 1, 2 -/- mice 
Deficiency of Period 1 and Period2 proteins result in lack of circadian 
rhythms in behavior and gene expression. (19, 24, 25). Period 2 deficiency 
increases genetic and radiation induced cancer susceptibility. Overexpression of 
Period 1 and period2 has shown to reduce tumor growth and promote apoptosis 
in vivo and in vitro (20, 26, 27, 28).It is observed that Period 1and 2 are 
downregulated in various human tumors. Therefore Period 1 and 2 are considered 
as tumor suppressor genes (20) Period 1 and 2 deficient mice also show certain 
features of premature aging such as faster decline in fertility, loss of soft tissues 
and kyphosis at 12-14 months of age (19, 25-29). 
1.7.3 Cry 1, 2 -/- mice 
Deficiency of Cry1 and Cry 2 also results in arrhythmic behavior. In contrary 
to the role of Period genes in tumor suppression, cry1 and 2 deficiency in p53 
deficient mice resulted in increased lifespan and resistance to cancer. It has been 
shown that deficiency of Cry1 and 2 promotes apoptosis after UV irradiation (20, 
30, 31, and 32). Cry1 deficient mice show reduced life span (our unpublished data). 
1.7.4 Clock -/- mice 
Recently our lab has shown that Clock deficient mice show a 15% reduced 
average lifespan with increased incidences of cataract and dermatitis. These mice 
have normal body weight and organ weights (20, 33). Other labs have shown that 
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Clock deficient mice do show arrhythmicity in peripheral tissues with period slightly 
shorter than 24 hr (20, 35, and 36). 
It has been reported that deficiency of CLOCK and its paralog NPAS2 
(double mutant) results in arrhythmicity in behavior both in central and peripheral 
oscillators. Mice display reduced life span and body weight and are sterile (20, 37-
40). 
All the circadian clock mutant mice are considered as models of disrupted 
circadian clock and we can expect each mutant to display abnormalities associated 
with general dysfunction of circadian clock. However, as discussed above, 
pathological conditions associated with each clock mutant are different. This 
indicates that circadian proteins might have a unique role in tissue homeostasis, 
which is independent of clock. Different phenotypes of circadian clock mutants 
suggests that deficiency of specific clock gene might demonstrate specific 
phenotype in addition to general abnormalities due to disruption of the circadian 
clock. 
 
1.8 Senescence and aging 
Accumulation of senescent cells in tissues has been observed with aging. 
It is believed that senescent cells can contribute to age-related pathologies (2, 41). 
Senescence (derived from the Latin word Sensex means old) is a specific 
metabolic state of cells characterized by certain changes described below. It was 
first described by Heyflick and Moorhead demonstrating that after definite number 
of divisions, embryonic derived human fibroblasts enter irreversible growth arrest 
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displaying limited proliferative potential in vitro. This is known as the Heyflick limit 
(2, 42, and 43). Other than humans, senescence is also demonstrated in other 
mammalian species and also in chicken cell cultures. Senescence also occurs in 
other cell types such as keratinocytes, glial cells, endothelial cells, vascular smooth 
muscle cells, lymphocytes and lens cells (42, 44-50). 
Senescent cells display the following specific characteristics: 
 Irreversible growth arrest: indicates limited proliferative potential and 
once the growth is arrested, it cannot be stimulated to reenter the cell cycle 
(43,51). 
 Metabolically active: It is demonstrated that senescent cells secrete 
various factors that can affect tissue physiology (44) 
 Resistant to apoptosis: Senescent cells have been shown to resist 
apoptosis and can remain viable for indefinite period(52,53) 
 Enlarged and flattened morphology: Senescent cells are enlarged and 
flattened. They also show an increase in the size of the nucleus and 
nucleoli, along with an increase in the number of Golgi and lysosomes and 
appearance of vacuoles in cytoplasm and endoplasmic reticulum (54). 
 Changes in the expression or activity of proteins: Proteins showing 
altered expression or activity in senescent cells are known as biomarkers 
of senescence. One of the commonly used biomarkers is SA-β Gal 
(Senescence associated β-galactosidase activity). β-galactosidase is a 
lysosomal hydrolase usually active at pH 4. Only in senescent cells and not 
in quiescent or non-senescent cells, β-galactosidase activity can also be 
17 
detected at pH6. There are other proteins such as matrix degrading 
proteases, chemokines and cytokines expressed in fibroblasts at senescent 
stage (55, 56, 57). 
Senescence can be divided into three different types, 1) Replicative, which 
results from limited proliferation of proliferating cells. It is considered to be due to 
telomere shortening. 2) Stress induced or premature senescence, which can occur 
due to oxidative stress or genotoxic stress from DNA damage. 3) Oncogene 
Induced senescence is considered as protective mechanism to avoid cell 
proliferation (Figure 4) (58-60) 
Previous studies based on cells explanted from old donors showed fewer 
population doubling than young donors, indicating that cells have an intrinsic 
counting mechanism. This mechanism limits cell proliferative potential after a 
definite number of doubling times. However, the role of replicative senescence has 
not been established in vivo. With extensive research in the field, senescence is 
believed to be a cellular state that can be induced by extrinsic factors such as 
various stresses and these factors also affect cellular intrinsic mechanism (61, 63, 
64, 65). It is also believed that stress-induced senescence is a tumor suppressor 
mechanism however, new role of stress-induced senescence can contribute to age 
associated senescence (2, 61). 
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Figure 4 : Different types of senescence  
Senescence can be divied into 3 types :1) replicative, occuring due to telomere 
dyfunction and loss of proliferative potential 2) Stress induced occurs due to 
oxidative or genotoxic stress and 3) Oncogene induced,whichoccurs due to 
oncogene activation and acts as a protective mechanism. 
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1.9 mTOR signaling pathway, metabolism, and aging 
TOR (Target of Rapamycin) signaling pathway is an evolutionarily 
conserved nutrient sensing pathway found from budding yeast to humans. As the 
name suggests, it was discovered as a target of Rapamycin. Rapamycin was 
discovered as an antifungal agent, produced by a strain Streptomyces 
hygroscopicus found in soil samples of Polynesian island Rapa Nui. Rapamycin 
was later recognized for its immunosuppressant and anti-cancer activity (66, 67, 
68, and 69). The physiological significance of mTOR is associated with its central 
role in regulating cellular processes in response to nutrients, growth factors, 
change in energy status, and stress conditions such as hypoxia. Its central role in 
metabolism makes mTORC1 crucial for normal growth and development. mTOR 
has been liked with many diseases such as cancer, metabolic diseases and aging 
(68-73). 
 
1.10 mTOR and Cancer 
As a regulator of cell growth and proliferation, mTOR plays an important 
role in cancer. Mutations in Tsc1 or Tsc2, upstream inhibitors of mTORC1 result 
in hamartomatous syndrome (multiple benign and malignant tumors) indicating link 
between mTOR and cancer (74, 75) 
PI3K/AKT signaling activates mTORC1. Oncogenic transformation by hyper 
activation of AKT signaling is mostly mediated by mTORC1 (76, 77). Dysregulated 
protein synthesis has been reported in cancer. 4EBPs (inhibitor of eIF4E) is a 
direct and eIF4B is an indirect target of mTORC1. Both proteins regulate the rate 
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of cap-dependent translation initiation. (72, 78). The concept of using Rapamycin 
(mTOR inhibitor) analogs for cancer treatment is growing. Rapamycin and its 
analogs, in combination with chemotherapy, are in clinical trials (79-80). 
1.11 mTOR and metabolic diseases 
Being a nutrients sensor, mTOR acts as a major regulator of metabolism. 
Under diverse nutrient conditions, mTORC1 downstream targets mediate different 
effects. Recent studies showed that excess nutrients results in insulin resistance 
and type II diabetes probably via mTORC1 target S6K1 (81, 82, 83, and 84). 
Studies with S6K1 deficient mice demonstrates its importance in growth 
development. S6K1 deficient mice are smaller at birth as compared with WT mice. 
They also demonstrate Hypoinsulinemia and reduced white adipose tissue due to 
reduced β and adipocyte cell size respectively (85). 
1.12 mTOR and senescence 
Increased cell size is a hallmark of senescence. mTORC1 is a major 
regulator of cell size and plays a critical role in cellular senescence. Rapamycin 
treatment has been shown to delay or inhibit cellular senescence. Another study 
with a mice model with constitutive Wnt signaling in epidermal compartment, 
showed mTOR dependent rapid growth of hair follicles followed by senescence 
that was inhibited by Rapamycin (86). 
1.13 mTOR and aging 
The role of mTOR in aging is like a double-edged sword. It is critical for 
growth and development but could be detrimental during late stages of life. Many 
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aging studies have shown that decreased mTOR activity leads to extended 
lifespan. In C.elegans and Drosophila, mutations with mTOR pathway genes have 
extended longevity (87, 88). Decrease in TOR signaling by low dose of Rapamycin 
lead to extended chronological life span of yeast (89). Interestingly, long lived 
Dwarf mice show downregulation of mTORC1 effectors in liver and skeletal muscle 
(90). The S6K1 deficient mice model is believed to a mimic food restriction model 
having extended life span and with females displaying increased a longevity, with 
less age related pathologies (91). Another study with Drosophila showed that 
overexpression of d4EBP results in increased longevity (92).To summarize, 
studies with inhibition of mTOR and its downstream targets show that mTOR plays 
a critical role in regulation of life span. 
1.14 mTOR kinase 
mTOR (mammalian target of Rapamycin, also known as FRAP, RAFT, 
RAPT) is a 289 kDa serine/threonine protein kinase and belongs to a family of PIK-
related kinases (phosphatidylinositol kinase-related kinases). Members of this 
family share strong homology of their C-terminal domain with catalytic domain of 
PI3K (phosphatidylinositol 3-kinase). Other members of this family include ATM, 
ATR, and RAD 53 (93, 94, 95). 
1.15 Domains of mTOR 
mTOR contains many functional domains involved in its function (Figure 5). 
At its N terminus, mTOR contains 20 tandem HEAT repeats. HEAT is abbreviated 
from Huntington, elongation factor 3, the A subunit of type 2A phosphatase 
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(PP2A), TOR. These HEAT motifs are believed to mediate protein-protein 
interactions. 
As mentioned before, C terminal contains a kinase domain that is highly 
conserved and displays serine/threonine kinase activity. It contain around 300 
residues region from amino acids 2115 to2446 (96, 97, and 98). 
To the N-terminal of kinase domain, mTOR contains a regulatory domain of 
approximately 100 amino acids (2015-2114 in human mTOR) known as FRB 
(FKBP12-Rapamycin Binding domain). FKBP12 also known as the FK506 binding 
protein is an immunosuppressant binding protein. The crystal structure of FKBP12-
rapamycin bound to FRB domain shows that Rapamycin simultaneously binds to 
the FRB domain and FKBP12 and inhibits mTOR. A mutation of the conserved 
Serine residue at aa2035 was shown to confer resistance to Rapamycin (97, 99). 
FAT (FRAP, ATM, TRRAP) is another domain in mTOR located at the N terminal 
of FRB and Kinase domain. It is around 500 amino acids and spans approximately 
1513-2014 aa in human mTOR. Crystal structure shows that it contains 3 domains 
(TRD1, TRD2, TRD3) from TRP repeat family and one HEAT family domain 
(HRD). Although the function of the FAT domain is not clear, it was proposed to be 
involved in protein –protein interactions. New crystal structure of mTOR shows 
FAT domain clamping on kinase domain, illustrating its importance.  
FATC (FRAP, ATM, TRRAP, Carboxy terminus) is a 35 amino acids long 
domain found at the extreme C terminus in mTOR. It usually occurs with FAT 
domain and might work with FAT in catalytic function in PIK-related kinases (97, 
99,100). 
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Between the kinase and FATC domain is a domain from amino acids 2427-
2516 known as FIT (Found in TOR) domain. It is also known as a regulatory 
domain due to presence of 3 phosphorylation sites, T2446, S2448, S2481(97). 
1.16 Phosphorylation sites of mTOR  
There are 4 important phosphorylation sites in mTOR involved in its regulation. 
1. T2446, found in the FIT domain that is probably regulated by AMPK 
depending on nutrient availability. 
2. S2448, found in the FIT domain and phosphorylated by its own target 
S6K1, depending on amino acid and nutrient status. 
3. S2481, found in the FIT domain that is autophosphorylated. This 
phosphorylation might be promoted by insulin signals. 
4. S1261, found in the HEAT domain is phosphorylated by insulin/PI3-K in 
amino acid dependent, Rapamycin insensitive and autophosphoryation- 
independent manner (97,100,101). 
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Figure 5 : Schematic representation of mTOR domains, interacting proteins 
and known phosphorylation sites. 
HEAT: Huntington elongation factor 3, PR65/A, TOR FAT: FRAP ATM TRRAP, 
FRB: FKBP12 Rapamycin binding, KD: kinase domain, RD: Regulatory domain, 
FATC: FRAP ATM TRRAP carboxyl terminus 
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1.17 mTOR complexes 
mTOR exists in two structurally and functionally distinct complexes: 
mTORC1 and mTORC2. They were identified based on sensitivity to Rapamycin, 
with mTORC1 being sensitive and mTORC2 Rapamycin insensitive. However, 
recent data suggests that mTORC2 also shows sensitivity to Rapamycin after 
prolonged treatment. mTORC1 and mTORC2 phosphorylate different target 
proteins (S6K1 and 4EBP1 by mTORC1, AKT, and SGK1 by mTORC2) whose 
phosphorylation is used as a readout for their activity. 
mTORC1 regulates various cellular processes such as protein synthesis, 
autophagy, metabolism, cell size, and cell proliferation. Compared to mTORC1, 
the role of mTORC2 is poorly understood (102,103). 
1.17.1 mTORC1 complex 
In addition to mTOR, mTORC1 complex consist of four other components: 
Raptor, mLST8, Pras40, and Deptor. Raptor (Regulatory-associated protein of 
mTOR) is a 150 KDa mTOR-binding protein involved in recruitment of mTOR 
substrates for phosphorylation. Raptor interacts with the N-terminal HEAT domain 
of mTOR for binding (104). 
mLST8 (mammalian homolog of lethal with sec-13 gene 8), also known as 
GβL (G protein β-subunit –like protein) is a 36 KDa protein that is a part of 
mTORC1 and mTORC2 complex. It binds mTOR in the kinase domain but its role 
is not clear. Recent data suggest that mSLT8 acts as a positive regulator of 
mTORC1; its deletion has no effect on mTORC1 activity (105). 
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PRAS40 (Proline-Rich AKT Substrate 40 kDa) is a 40 kDa protein which 
acts as a negative regulator and physiological substrate of mTORC1. It binds to 
mTOR at its kinase domain. It also binds to Raptor using TOS like motif and 
competes with mTORC1 substrates for Raptor substrate binding sites. In response 
to insulin, AKT phosphorylates PRAS40 at T246 which facilitates its 
phosphorylation by mTORC1 on S183.  Phosphorylation by AKT and mTORC1 
results in dissociation of PRAS40 from mTORC1, resulting in activation of 
mTORC1 (106). 
DEPTOR (DEP domain containing mTOR interacting protein) is a 48 kDa 
protein, which was recently identified as a negative regulator of mTOR. It is part of 
both mTORC1 and mTORC2 complexes. DEPTOR has two domains a N terminal 
DEP (Disheveled, Egl-10, Pleckstrin) and a C-terminal PDZ (Postsynaptic density 
95, Discs large, Zonula occludens-1). DEPTOR specifically interacts with mTOR 
at the C terminal portion upstream of kinase domain via the PDZ domain. DEPTOR 
doesn’t react with mLST8, which is a common component of both complexes. 
Downregulation of DEPTOR by shRNA results in increased mTORC1 and 
mTORC2 activity, as indicated by phosphorylation of their specific targets 
(107,108). 
Effectors of mTORC1 
mTORC1 phosphorylates many downstream targets. The two best known 
mTORC1 substrates are S6 kinase 1 and 4EBP proteins. S6K1 is an AGC family 
member that is encoded by s6k1 gene. Out of 7 known phosphorylation sites, 
mTORC1 specifically phosphorylates S6K1 at T389, which is present in the 
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hydrophobic region and is important for stimulation of S6K1activity. Activated S6K1 
promotes mRNA translation through various substrates such as ribosomal protein 
S6, SKAR, eEF-2K, eIF4B and PDCD4. S6K1 phosphorylates ribosomal protein 
S6 on four phosphorylation sites, S235, S236, S240 and S244.  Phosphorylation 
of S6 at the mentioned four sites is also used as readout for mTORC1 activity 
(77,109,110). 
4EBPs (eIF4E- binding proteins) are translation repressors consisting of 3 
proteins 4EBP1, 4EBP2 and 4EBP3 that are encoded by three different genes. 
Though all three forms are phosphorylated by mTORC1, 4EBP1 is the most 
studied form.  Hypo phosphorylated 4EBPs have high affinity for eIF4E and their 
binding prevents its interaction with eIF4G required for Cap-dependent protein 
translation initiation. Phosphorylation of 4EBPs result in dissociation from eIF4E. 
Out of four known phosphorylation sites, mTORC1 have been shown to 
phosphorylate 4EBPs on two sites (T37, T46) in vitro which is required for further 
phosphorylation on T70 and S65 in a hierarchical manner. We have used 
antibodies against phosphorylation at Thr37/46 as a readout of mTORC1 activity 
(97,111,112). 
1.17.2 mTORC2 complex 
In addition to mTOR, this complex contains many other proteins such as 
Rictor, Protor, and mSIN1, which are not present in the mTORC1 complex. mLST8 
and DEPTOR are found in both complexes. 
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Rictor (Rapamycin Insensitive Companion of TOR) is approximately 200 kDa 
protein, which competes with Raptor for mTOR binding. It is also considered to 
confer Rapamycin insensitivity to mTORC2 (113). 
Protor-1 (Protein observed with Rictor-1 also known as PRR5) is 42kDa protein 
that binds to Rictor. Protor exists in 2 isoforms, both of which can bind to Rictor. 
Protor is not required for mTORC2 complex stability or activity (114). 
mSIN1 (mammalian Stress activated protein kinase interacting protein) is a 57 kDA 
protein that forms a complex with Rictor. mSIN1 is shown to modulate Rictor 
phosphorylation, which helps in stabilization of mTORC2 complex. mSIN1 is also 
important for mTORC2 activity (115). 
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Figure 6 : Components of mTOR complex1 and mTOR complex 2 
Both complexes have some common components, mTOR: mammalian target of 
Rapamycin, DEPTOR: DEP domain containing mTOR interacting protein, mLST8: 
Mammalian homolog of lethal with sec-13 gene 8. 
mTORC1 complex components are Raptor (Regulatory associated protein of 
mTOR), PRAS-40 (Proline Rich AKT substrate 40 KDa) 
mTORC2 complex components are Rictor (Rapamycin insensitive companion of 
TOR), Protor-1 (Protein observed with Rictor 1), mSIN1 (mammalian stress 
activated kinase interacting protein 1) 
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1.18 Regulation of mTORC1 pathway 
mTORC1 acts as a central sensor for cells integrating various signals from 
growth factors, nutrient availability, energy status, glucose, oxygen and that 
regulates many physiological functions such as metabolism. It is an evolutionary 
conserved pathway that responds to nutrients. (101-103,116) 
Most of the upstream signals regulate mTORC1 by two mechanisms 
1. Direct modification of mTORC1 components 
2. Regulation of RHEB. 
Recently, the role of Rag–Ragulator complex in mTORC1 localization and   
activation has been demonstrated. Rags are small GTP-binding proteins that play 
an important role is activation of mTORC1 by amino acids. Recently, the newly 
discovered Rag GTPases (RagA-D) represent a key development in 
understanding of mTORC1 regulation by amino acids. They act as heterodimers 
either of Rag A or B (Rag A and B are redundant in function) with Rag C or D (Rag 
C and D are redundant in function) and reside on lysosomal membrane with the 
help of Ragulator (multimeric complex of MP1, p14, p18). In amino acid deprivation 
condition, RagA/B is bound to GDP and RagC /D to GTP (117-120). 
Amino acids induce change in the nucleotide-bound status of Rag proteins by 
unknown mechanism resulting in RagA/B bound to GTP and RagC/D to GDP, 
indicating active state of heterodimer. The RagB-GTP/RagC-GDP heterodimer is 
shown to be the most effective one. The active heterodimer serves as a docking 
site on the lysosomal surface for mTORC1 through interaction with Raptor where 
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mTORC1 can interact with Rheb-GTP for its activation. As activation of mTORC1 
by Rheb is also an upstream event for other signaling pathways such as by growth 
factors, localization of mTORC1 to lysosome by Rags might be the key event in 
mTORC1 signaling (118-121). 
  
32 
Current model of mTORC1 pathway 
 
Figure 7 : Current model of mTORC1 signaling pathway 
Various signals such as Amino acids, growth factors, energy stress, and hypoxia 
regulate the mTORC1 pathway. Amino acids regulate mTORC1 via the Ragulator-
Rags complex by lysosomal localization. Rheb is a small GTPase that acts as a 
positive regulator of mTORC1 and is negatively regulated by the TSC1/TSC2 
complex via GAP activity of TSC2 towards Rheb. Activity of the TSC1/TSC2 
complex is regulated by phosphorylation of TSC2 on specific sites. Activated 
mTORC1 complex can phosphorylate its substrates such as S6K1 and 4EBP1. 
Phosphorylation of S6K1 at T389 and phosphorylation of 4EBP at T37 and T46 
are used as a readout for mTORC1 activity. Phosphorylation of ribosomal protein 
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S6 at 4 sites (S235, S236, S240, and S244) by S6K1 is also used as a marker for 
mTORC1 activity. 
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1.19 Upstream Regulators of mTORC1 
To understand mTORC1 signaling, its upstream regulators, effect of various 
signals and well known downstream effectors of mTORC1 involved in cellular 
functions will be discussed. 
1.19.1 TSC2/TSC1 complex: 
TheTSC2/TSC1 complex is a negative regulator of mTORC1 
signaling.TSC2, also known as Tuberin is encoded by the Tuberous Sclerosis 
Complex 2 gene and TSC1 also known as Hamartin, is encoded by the Tuberous 
Sclerosis Complex 1 gene; both are tumor suppressor genes. Their mutations 
result in a genetic disorder known as Tuberous Sclerosis Complex characterized 
by benign tumors containing large cells in different tissues (123). TSC2 and TSC1 
are phosphoproteins. Various kinases have been reported to act more on TSC2 
compared with TSC1. TSC2 also shows GAP (GTPase activating protein) towards 
RHEB (positive regulator of mTORC1) When TSC2/TSC1 complex is active it 
stimulates a change of Rheb-GTP to Rheb-GDP and inhibits mTORC1 activity. 
TSC1 does not have GAP activity and it is considered to be important for stabilizing 
TSC2 by forming a complex (124-127). In response to growth factors, TSC2 is 
phosphorylated by AKT on at least 5 different sites (S939, S981, S1130, S1132, 
T1462) resulting in its repression. The effect of TSC2 phosphorylation on its GAP 
activity is not clear (128). 
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1.19.2 RHEB  
Rheb (Ras Homolog Enriched in brain) is a small GTPase protein which 
acts as a positive regulator of mTORC1. It belongs to the RAS superfamily and is 
conserved in eukaryotes. Even though the name suggests brain, Rheb is 
ubiquitously expressed in all tissues. It has an intrinsic GTPase activity thereby 
hydrolyzing GTP to GDP. This activity is stimulated by the GAP activity of TSC2 
(125,129). It has been shown that both GDP- and GTP- bound Rheb, and even 
nucleotide free Rheb, can bind to mTORC1, but only GTP-bound Rheb can 
activate mTORC1(121,130). 
1.20 Upstream signals in regulation of mTORC1 
1.20.1 Growth factors signaling 
It is well known that growth factors such as insulin and IGF-1 can activate 
mTORC1 signaling via the PI3K-AKT pathway. When growth factors are available, 
mTORC1 promotes anabolic processes such as protein synthesis, lipid 
biosynthesis, and nutrient storage (101-103). In presence of growth factors, 
activated AKT can phosphorylate TSC2 on at least 5 sites (S939, S981, S1140, 
S1132, and Thr1462). S939 and T1462 are shown as specific AKT sites and are 
conserved among species but other sites responsible for regulation of TSC2/TSC1 
complex might exist. How TSC2 phosphorylation affects TSC2/TSC1 complex and 
its activity towards Rheb is not clear. Moreover, it has been shown that 
phosphorylation of TSC2 doesn’t change its GAP activity towards Rheb. Another 
study suggested a possible alteration in TSC2 subcellular localization by 
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phosphorylation, so it cannot act as GAP for Rheb. TSC1 has a transmemebrane 
domain that mediates localization of the TSC1/TSC2 complex in the membrane 
region. Many AKT targets are regulated by creating binding sites for 14-3-3 
proteins after phosphorylation. One study suggested that phosphorylation of TSC2 
on both S939 and Thr1462 is required for binding with 14-3-3 proteins. This binding 
results in dissociation of the TSC1/TSC2 complex and translocation of 
phosphorylated TSC2 (S939/S981) at cytosol alone. This disrupts physical 
proximity of TSC2 and Rheb, so TSC2 can no longer act as Gap for Rheb at the 
membrane, thus resulting in activation of Rheb. (131,132). mTORC1 is also 
regulated by growth factors via TSC2 independent mechanisms. Growth factor-
activated AKT phosphorylates PRAS40, resulting in inhibition of its repression on 
mTORC1 (133). 
A recent study demonstrated that in response to growth factors, 
accumulation of Phosphatidic acid (PA) in phospholipase-D (PLD)-dependent 
manner, results in activation of mTORC1. It was also shown that PA binds to the 
FRB domain of mTOR. Other data suggest that PA activation of mTORC1 might 
be dependent on TSC2, as loss of TSC2 results in activation of PLD-1 (134,135). 
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Figure 8 :  Activation of mTORC1 complex by growth factors 
Growth factors such as Insulin and Insulin like growth factors activate the PI3K-
AKT pathway. Activated AKT phosphorylates TSC2 on two conserved sites S939 
and Thr1462, resulting in inhibition of the TSC1/TSC2 complex. Inhibited complex 
can’t act as GAP (GTPase activating protein) for Rheb resulting in Rheb-GTP. 
Rheb-GTP activates mTORC1. Activated AKT also phosphorylates PRAS40 which 
negatively regulates mTORC1. Phosphorylation of PRAS40 results in its 
dissociation from mTORC1 and activation of mTORC1. 
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1.20.2 Glucose and Energy 
Along with mTORC1 signaling, anabolic processes require energy in the 
form of ATP. Glucose deprivation also leads to lower ATP levels. Low ATP results 
in a higher AMP/ATP ratio, resulting in binding of AMP to AMP activated protein 
kinase (AMPK) and triggering its phosphorylation by LKB1. Activated AMPK 
phosphorylates TSC2 on S1387 and T1271 resulting in activation of TSC1/TSC2 
complex and inhibition of mTORC1 through unknown mechanism (136,137). 
Another study demonstrated that phosphorylation of TSC2 on S1387 
primes it for further phosphorylation on 4 sites by glycogen synthase kinase 3β 
(GSK3β), which is regulated by Wnt signaling. This results in activation of 
theTSC1/TSC2 complex and inhibition of mTORC1. Wnt signaling inhibits GSK3β 
and can activate mTORc1 signaling. However, the physiological condition leading 
to cross talk between energy sensing and Wnt signaling is not clear (138). 
mTORC1 can sense energy depletion independent of TSC2, partly by 
phosphorylation of Raptor on two conserved residues by activated AMPK. 
Phosphorylation of Raptor induces binding of 14-3-3 to raptor and inhibition of 
mTORC1 by a poorly understood mechanism (139). 
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Figure 9 : Low Glucose and energy levels result in an inactive mTORC1 
complex 
Low glucose or energy result in lower levels of ATP and increased AMP/ATP ratio. 
This results in activation of the AMP kinase (AMPK) by LKB1. AMPK 
phosphorylates TSC2 on S1387 and T1271 resulting in activation of TSC1/TSC2 
complex. This complex stimulates Rheb-GTP to Rheb-GDP, resulting in 
inactivation of mTORC1. 
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1.20.3 Hypoxia (Low Oxygen level) 
mTORC1 is inhibited by low oxygen levels (hypoxia). Hypoxia results in 
inhibition of aerobic ATP production resulting in reduction of cellular ATP levels, 
resulting in activation of AMPK and inhibition of mTORC1, as described above.  
Another mechanism involves REDD1, a cytoplasmic protein which is induced 
under hypoxic conditions (123). Recently it was demonstrated that REDD1 
reverses AKT-mediated inhibition of TSC1/TSC2 complex. REDD1 activates the 
TSC1/TSC2 complex by moving 14-3-3 proteins bound on two AKT 
phosphorylation sites on TSC2 (S939, Thr1462) (140,141). Other pathways also 
have been proposed for suppression of mTORC1 by hypoxia, but more information 
is required. 
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Figure 10 : Hypoxia results in inactivation of mTORC1 
Hypoxia induces HIF1α transcription factor which induces REDD1. REDD1 moves 
14-3-3 proteins away from TSC1/TSC2 complex resulting in activation of complex. 
This complex stimulates Rheb-GTP to Rheb-GDP resulting in inactivation of 
mTORC1. 
  
42 
 
CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Animal Experiments 
All animal experiments were conducted in accordance with regulations of 
IACUC at Cleveland State University. C57BI/6J mice were a gift from Dr. Bradfield 
and Dr. Marina Antoch. Bmal1-/- mice have been previously described. In all 
experiments male mice between ages of 3-6 months were used. Unless otherwise 
noted, all mice were maintained under standard animal housing conditions, with 
free access to food and water in 12 hours light/ 12 hours dark cycles. For time 
restricted feeding experiments, definite amount of food (95% of daily consumption) 
was provided at ZT14 (2hrs after lights were off). All mice were kept for 2 weeks 
with restricted feeding regimen before starting experiments. For all experiments, 
animals were euthanized using CO2 chamber standard protocol dictated by 
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Cleveland State University. For starvation experiments, definite amount of food 
(95% of daily consumption) was provided at ZT14 and then no food was provided 
for next 48 hrs. Animals were sacrificed every 2 or 4 hr within this period. 
 
2.2 Tissues, Cells and Cell culture 
  All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % Fetal Bovine serum (FBS) and 10,000 units of Penicillin 
G and 10,000 µg/ml streptomycin. Cells were maintained at 37˚C at 5% CO2 
condition. 
  To generate primary lung fibroblasts, lung tissues isolated from WT and 
Bmal1-/-mice were cut into small pieces and plated in DMEM media. After 72 hr, 
media was replaced to remove unattached cells. Then cells were passaged every 
3 days. During each passage, cells were counted and plated at equal density in 
each plate during every passage Cells were immortalized by passaging and then 
immortalized cell lines were used for experiments. 
To collect tissues, after sacrificing animals, tissues were quickly frozen on 
dry ice and stored in -80˚C. For histological purpose, isolated tissues were 
immediately frozen in OST solution. 
2.3 Senescence associated β-gal staining detection 
Accumulation of senescent cells is used as cellular marker of aging. 
Senescent cells in isolated tissues were detected using senescence associated β-
gal staining (SA-βGal) using a previously described protocol (56). Briefly, animals 
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were sacrificed and tissues were immediately frozen using OST solution. Four µm 
sections were fixed in 4% paraformaldehyde/PBS solution and stained using a x-
Gal/potassium Ferro cyanide/potassium ferricyanide protocol. Stained tissue 
sections were analyzed under microscope and photographed. The number of blue 
cells was counted by 3 people independently blind to genotype. Sections were 
counterstained with hematoxylin /eosin according to standard protocol.  
2.4 Replicative senescence  
Replicative senescence represents primary cell growth arrest in cell culture. 
For measuring replicative senescence, primary lung fibroblasts from WT and 
Bmal1-/-mice were isolated as mentioned before. Cells were split as per standard 
3T3 protocol. Briefly cells were passaged every 3 days and during each passage, 
cells were counted using hem cytometer and all cells were plated again at density 
of 104/cm2. The procedure was followed until the time, the cells became 
immortalized. (n=16 8WT 8 KO). Cell number at each passage was used as 
measure of cell proliferation. Reduction in number of cells after few passages was 
used as an indication of senescence and was confirmed using SA-βgal staining. 
2.5 Oxidative stress sensitivity assay 
For the assay, WT and Bmal1-/- cells were plated at 1000 per well in three 
96-well culture dishes. At 24 hr. after plating, cells were treated with different 
concentrations of Hydrogen peroxide (Sigma Aldrich H1009-500ML) for 24, 48 and 
72 hr. Treated cells were washed with PBS and fixed using 0.2% Glutaraldehyde 
prepared from 25% Glutaraldehyde (Fisher Scientific) by diluting in PBS. Fixed 
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cells were stained using 0.05% crystal violet solution for 30 min on shaker. Dye 
was extracted using 1% SDS (Invitrogen) solution and amount of dye incorporated 
was measured as optical density at 570 nM using a Victor 1420 plate reader. 
2.6 Colony forming assay 
To check effect of oxidative stress on cell proliferation, we performed colony 
forming assay. WT and Bmal1-/- immortalized lung fibroblasts were plated at a 
density of 10000 per well on 6-well culture dishes. Next day after plating, one well 
of each WT and Bmal1-/- was either treated with DMEM (untreated) for 96 hr, or 
in presence of 250 nM Hydrogen Peroxide for 96 hr, or in presence of 250 nM 
Hydrogen Peroxide for 24 h. and then regular media for next  72 hr. After 96 hr of 
treatment, cells were washed with PBS, fixed using 0.2% Glutaraldehyde and 
stained using 0.05% Crystal Violet solution for 30 min on shaker. Dye was 
removed, plated cells were washed gently with water to remove excess dye and 
air dried. Stained colonies were counted by 3 people independently blind to cell 
genotype. 
2.7 Cell death assay 
Damaged cell membrane and leakage of intracellular contents in media are 
indications of cell death. In this assay, membrane damage was detected using the 
CytoTOX-ONETM Homogenous Membrane integrity assay (Promega). Briefly, WT 
and Bmal1-/- immortalized lung fibroblasts were plated at a 1000 density in 96-well 
culture plates. After 24 hr following plating, fibroblasts were either treated with 
DMEM, or with different concentrations of Hydrogen Peroxide for 4Hrs. in the 37˚C 
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incubator. After 4Hr of incubation, positive control wells were treated with Lysis 
solution reagent provided by manufacturer as a positive control for cell death. 
Equal volume of CytoTOX-ONETM   was added in each well and mixed on shaker 
for 30 sec. Plates were incubated at room temperature for 10 min and fluorescence 
was recorded using Victor 1420 plate reader. The fluorescence was recorded 
every 10mins for 1 hr.  
2.8 Anticancer Drugs sensitivity assay 
To examine changes in genotoxic stress resistance of Bmal1-/- fibroblasts, we 
used different anticancer drugs. These drugs were chosen in such a way that they 
act through different pathways and affect cell proliferation or cell death through 
different mechanisms. Following drugs were used, 
 Paclitaxel (Taxol): Microtubule stabilizing agent 
 5-Fluorouracil: Antimetabolite  
 Etoposide: DNA damaging by producing double-stranded breaks 
  Daunorubicin: Antimitotic activity 
For the assay, WT and Bmal1-/- immortalized lung fibroblasts were plated at 1000 
per well in three 96-well culture dishes. Twenty four hours after plating, cells were 
treated with different concentrations of either Paclitaxel, 5-Flurouracil, Etoposide 
or Daunorubicin (Sigma-Aldrich) for 24, 48 and 72 hrs. Cell survival was estimated 
using two independent protocols, the MTT assay and Crystal Violet staining. The 
MTT assay was performed using In Vitro Toxicology assay kit (Sigma M6555) as 
per manufacturer’s protocol. Briefly, the MTT reagent was reconstituted using 
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media just before use. Reconstituted reagent was added to treated plates in equal 
amount (10% of each culture volume).These cells were incubated for 2 hr and 
absorbance was measured at 570 nM using a Victor 1420 plate reader.  
In crystal Violet staining, treated cells were washed with PBS twice and fixed using 
0.2% Glutaraldehyde prepared from 25% Glutaraldehyde (Fischer Scientific). 
Fixed cells were stained using 0.05% crystal violet solution for 30 minutes on 
shaker. The dye was removed and excess dye was washed out by water. 
Incorporated dye was extracted by adding 1% SDS solution and shaking for 30 
min on shaker. The incorporated dye was measured as optical density at 570 nM 
using Victor 1420 plate reader. 
2.9 Rapamycin Sensitivity assay 
Rapamycin (Sigma–Aldrich) was used as mTOR inhibitor. WT and Bmal1-
/-immortalized lung fibroblasts were plated at equal density in three 96 well plates. 
One plate was fixed after 6 hr of plating as control. For fixing, media was removed 
and cells were washed with PBS twice and fixed with 0.2% glutaraldehyde. Two 
96 well plates were treated with different concentrations of Rapamycin for 24 and 
48 hr. Treated cells were stained and  the dye was extracted as indicated in section 
2.5. Optical density reading was used as indication of cell proliferation (the high 
optical density represents more cell proliferation). 
2.10 Protein content determination 
Plated WT and Bmal1-/- immortalized lung fibroblasts were trypsinized and 
collected in DMEM media. Cells were counted and an equal number of WT and 
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Bmal1-/- cells were collected in micro centrifuge tubes. We prepared different sets 
of WT and Bmal1-/- samples with different number of cells. Collected cells were 
washed twice in PBS and lysed using equal volume of RIPA buffer. Protein 
concentrations of cell lysates were measured using protein assay reagent (BIO-
RAD 500-0006) using spectrophotometer. 1mg/ml albumin solution was used to 
make standard curve. 
2.11 Western blotting analysis 
2.11.1 Cell Lysates 
WT and Bmal1-/- immortalized lung fibroblasts were plated at a density of 
400,000 in 100 mm culture dishes. After 24 hr of plating, cells were treated as 
described in each experiment. Cells were washed twice with PBS and collected in 
1ml PBS per tube. Tubes were centrifuged at 6000 rpm for 10 minat 40 C using 
Eppendorf 5417R centrifuge. Supernatant was discarded and pellet was re-
suspended in 50-100 µl RIPA lysis buffer (Tris Base pH 7.4 10mM, NaCl ,EDTA 
pH8, NaF, 20 % SDS,Triton-X100,glycerol water). Just before use, Protease 
inhibitor cocktail (Sigma), Phosphatase inhibitor Cocktail2 (Sigma-Aldrich) at a 
concentration of 10 µl/ ml of buffer were added. Cell pellets were lysed by vortexing 
for 4-5 min. Lysates were centrifuged for 12 min at 10000rpm, 40C. Supernatants 
were used for protein concentration determination and lysates were stored at -800 
C.  
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2.11.2 Tissue Lysates  
Different tissues from WT and Bmal1-/- mice were collected over 24 period 
with interval of 4 hr. Tissues were quick frozen on dry ice and stored at -800C. For 
tissues lysates, a small piece was transferred into micro centrifuge tubes with 300 
µl Cell Signaling Buffer (Tris pH 7.5, NaCl, 0.5M EGTA, 0.5 M EDTA, Triton-x 100, 
Na4P2O7, β-glycerophosphate, 1M Na3VO4). Just before use, Protease inhibitor 
(Sigma), Phosphatase inhibitor Cocktail2 (Sigma-Aldrich) at a concentration of 10 
µl/ ml of buffer were added. Tissues were lysed using a sonicator (Fischer 
Scientific Model 100) for 5-10 seconds on ice. Lysates were centrifuged for 12 min 
at 10000 rpm at40C. Supernatants were used for protein concentration 
determination and lysates were stored at -800C. 
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Protein concentrations of lysates were measured using the protein assay 
reagent (BIO-RAD 500-0006) as per manufacturer’s instructions. Following protein 
concentration determinations, lysates were denatured using 2x Loading mix (300 
mM Tris HCl PH6.8, 10% SDS, 50% Glycerol, 10% 2-mercaptoethanol, 0.0025% 
Bromophenol blue) and cell signaling buffer to adjust equal concentration of protein 
in all lysates. Proteins were separated using 4-12% NuPAGE Bis-Tris precast gels, 
starting at 90V and then at 145V (SDS-PAGE). Samples were transferred 
electrophoretically at 110 mA for 70 min on Polyvinylidene Difluoride membrane 
(Thermo Scientific 88518) using transfer buffer containing 20% methanol, Tris 
Base 3g/L, Glycine 14.4g/L. After transfer, membranes were placed in blocking 
solution of 5% non-fat dry milk in TBS-T buffer (Tris Base 60.57 g/L, NaCl 87.66 
g/L PH adjusted to 7.4 with HCl and 0.1% Tween-20) for 1 hour at room 
temperature on shaker. Blots were incubated with specific primary and secondary 
antibodies as described in the table below (Table1). Western blotting analysis was 
performed using Clarity TM Western ECL Substrate (BIO-RAD) as instructed by the 
manufacturer and bands were visualized using Scientific Imaging film (Denville) 
and Odyssey FC imaging system (LI-COR). Bands were quantified using LI-COR 
software. 
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Table 1: Antibodies for Western Blotting 
Antibody Phosphor
ylation 
Site 
Dilution Washings Catalogue  Company 
P-mTOR S2448 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
2971 Cell 
Signaling 
P-mTOR S2481 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
2974 Cell 
Signaling 
mTOR Total 1:1000 in 5% 
BSA  
at 4° overnight  
3 
washings  
5 minutes 
each 
2972 Cell 
Signaling 
P-TSC2 T1462 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
3614 Cell 
Signaling 
TSC2 Total 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
3990 Cell 
Signaling 
P-S6K1 T421/S42
4 
1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
9204 Cell 
Signaling 
P-S6K1 T389 1:3000 in 5% 
Milk  
at 4°overnight  
3 
washings  
5 minutes 
each 
9206 Cell 
Signaling 
S6K1 Total 1:1000 in 5% 
BSA at  
4°overnight  
3 
washings  
5 minutes 
each 
2708 Cell 
Signaling 
P-S6 235/S236 1:5000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
2211 Cell 
Signaling 
P-S6 S240/S24
4 
1:5000 in 5% 
BSA at  
4°overnight  
3 
washings  
5 minutes 
each 
2215 Cell 
Signaling 
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S6 Total 1:5000 in 5% 
Milk  
at 4°overnight  
3 
washings  
5 minutes 
each 
SC-74459 Santa 
Cruz 
P-4EBP1 T37/46 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
2855 Cell 
Signaling 
4EBP1 Total 1:1000 in 5% 
BSA  
at 4°overnight  
3 
washings  
5 minutes 
each 
9452 Cell 
Signaling 
Deptor Total 1:1000 in 1% 
BSA + 1% milk  
at 4°overnight  
3 
washings  
5 minutes 
each 
NBP1-
49674 
Novus 
biological
s 
Rheb Total 1:1000 in 1% 
BSA + 1% milk  
at 4°overnight  
3 
washings  
5 minutes 
each 
4935 Cell 
Signaling 
B-Actin Total 1:30000 in 5% 
BSA  
1 hour Room 
temp. 
3 
washings  
5 minutes 
each 
A5441 Sigma-
Aldrich 
GAPDH Total 1:30000 in 5% 
BSA  
1 hour Room 
temp. 
3 
washings  
5 minutes 
each 
5174 Cell 
Signaling 
 
2.12 Semi Quantitative RT-PCR 
Total RNA was extracted from frozen tissue, using Trizol (Invitrogen) 
reagent as per manufacturer’s instructions and some modifications. Briefly, for 
every piece of tissue 1 ml of Trizol reagent was used. Tissues were homogenized 
with pestle (Sigma-Aldrich) for at least 5 minutes or until the entire tissue was 
homogenized. This was done keeping tubes on ice. Tubes were spun at 40C at 
11500 rpm for 10 min. Supernatants were transferred into new tubes and 
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incubated at room temperature for 5 minutes. After adding 200 µl chloroform 
(Fischer scientific), tubes were shaken vigorously and incubated for 2-3 minutes 
at room temperature. After spinning for 15 minutes at 11500 rpm at 40C, the 
aqueous phase was transferred into a new tube. The RNA was precipitated by 
adding 500 µl isopropanol. RNA was washed using 70% ethanol and pellet was air 
dried for 5 minutes. The pellet was re-suspended in 30 µl of RNAse free water. 
The RNA concentration was determined using Nano drop. Following quantification, 
a 20µl reverse transcription reaction contained 1µg of RNA, superscript III 
(Invitrogen),DNTPs, Random hexamers, DTT and 5X manufacturer’s buffer as per 
manufacturer’s instructions . Real time PCR reaction was performed using forward 
and reverse primers (IDT), 0.5 µl cDNA and SYBRGreen PCR Super mix (BIO-
RAD).Every reaction was performed in triplicates, amplified and quantified using 
Opticon 2 quantitative real time PCR system (MJ research).The Relative mRNA 
abundance was calculated using the comparative delta-Ct method with 18S RNA 
as standard.
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 Table 2: Primers for PCR 
mtor Forward ATT CAA TCC ATA GCC CCG TC 
 
Reverse TGC ATC ACT CGT TCA TCC TG 
deptor Forward GTG GTT CTC AGG CAT TCT ATC TC 
 
Reverse TGG GTA GGT TTT GAG ATG GTG 
 
18s rRNA Forward GCT TM TU GAC TCA ACA CGG GA 
 
Reverse AGC TAT CM TCT GTC AAT GTC 
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CHAPTER III 
RESULTS 
 
3. A. The circadian clock protein BMAL1 regulates cellular senescence in 
vivo. 
3. A.1 Bmal1 deficiency results in increased number of senescent cells in 
vivo. 
Previously, our lab has shown that BMAL1 deficiency results in reduced 
lifespan and many age-related pathological conditions such as Sarcopenia 
(reduced skeletal mass), cataract, reduced memory, calcification and ossification 
of joints, thus linking circadian clock with aging. Other labs have shown that 
senescent cells accumulate with aging in vivo. Senescent cells are characterized 
by arrested cell proliferation, enlarged morphology, resistance to apoptosis and 
change in expression of proteins known as markers of senescence.  
These findings lead us to hypothesize that the circadian clock protein BMAL1 may  
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play a critical role in cellular senescence, which contributes to premature aging in 
Bmal1-/- mice. To test this hypothesis, we used different tissues (liver, lung, 
spleen) collected from 6-10 months old WT and Bmal1-/- mice. At this age, Bmal1-
/- mice show multiple features of premature aging. Tissues were processed and 
stained for Senescence associated β-galactosidase staining (SA-β-gal). We 
observed that the intensity of blue staining developed in Bmal1-/- mice tissues was 
higher compared with WT tissues of the same age used as control, indicating a 
high SA-β-gal activity in Bmal1-/- mice (Figure11A Khapre R V et al. Cell cycle. 2011 Dec 
1; 10 (23):4162-9.We counted the number of blue cells (SA-β-gal positive) in stained 
liver and lung tissues under the microscope and plotted as graph (Figure 11B).The 
difference in number of SA-β-gal positive cells was about 3 fold higher in lungs and 
liver but no clear difference obvious in the spleen. This indicates that accumulation 
of senescent cells is tissue-specific. We also stained lung tissues obtained from 1 
month old WT and Bmal1-/- mice and found that even at this age when Bmal1-/- 
mice do not show any signs of premature aging, SA-β-gal activity was higher (Data 
not shown). These results supported our hypothesis that Bmal1-/- deficiency 
results in the accumulation of senescent cells in different tissues correlating with 
premature aging in Bmal1-/- mice. 
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A. Figure (A) 
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B. Figure (B) 
     
Figure 11 : Bmal1 deficiency leads to accumulation of senescent cells in 
vivo.  
Representative histological images of lung (left panel), Liver (middle panel), spleen 
(right panel) isolated from 6 months old WT mice (upper row) and Bmal1-/- (lower 
row) stained for SA-β-gal staining. (A) Collected tissues were stained and images 
were captured. 
(B) Number of blue stained cells were counted by three individuals blind to the 
genotype and results are plotted as mean + std. deviation (n= 10. 5WT 5KO).In 
case of lungs mean of SA-β-gal positive cells in WT is 8.8 + 2.4 whereas in Bmal1-
/- is 24.6 + 6.6. In liver mean of SA-β-gal positive cells in WT is 18.6 + 7.8 whereas 
in Bmal1-/- is 62.6 + 4.7. (*) indicates p< 0.05 
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3. A.2 Bmal1 deficiency does not affect cellular replicative senescence in 
vitro 
Once we observed the increased accumulation of senescent cells in vivo in 
Bmal1-/- mice, next we wanted to determine if Bmal1 deficiency affects 
senescence in vitro. When primary cells are cultured in vitro, they demonstrate 
limited life span and undergo replicative senescence after dividing for definite 
number of times. We hypothesized that if tissues from Bmal1-/- mice show higher 
accumulation of senescent cells then primary cells isolated from Bmal1-/- tissues 
will undergo replicative senescence earlier compare with WT cells in culture. For 
this purpose, we decided to use primary lung fibroblasts from WT and Bmal1-/- 
mice for two reasons: 1) we had observed increased accumulation of senescent 
cells in Bmal1-/- lung tissues 2) Fibroblast are a well-known model for studying 
senescence. 
For isolating lung fibroblasts, we cut lung into very small pieces and cultured 
them in DMEM.  Everyday culture plates were examined for isolation of fibroblasts 
from tissue pieces. In 3-4 days, when some fibroblasts were attached, half volume 
of media (DMEM) was replaced with new media. This was done to provide more 
nutrients but at the same time, to retain growth factors secreted by fibroblasts in 
culture. After 5 days of isolation, fibroblasts were split for the first time as first 
passage. After the first passage, cells were passaged every 3 days following NIH 
3T3 protocol. During every passage, number of cells was counted using 
hemocytometer and all the cells were plated again at equal density. The procedure 
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was repeated until cells were immortalized. As expected, most of the fibroblasts 
from WT and Bmal1-/- mice did undergo senescence. But when we compared 
proliferation curves and the onset of replicative senescence between WT and 
Bmal1-/-fibroblasts, we observed no significant difference (Figure 12 A from Khapre 
R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9). This indicated that Bmal1 deficiency 
might not significantly affect cellular replicative senescence in vitro and most likely 
does not contribute to increased cellular senescence in vivo in Bmal1-/- mice. 
It is known that mouse primary fibroblasts can spontaneously immortalize 
in culture. As expected, our WT and Bmal1-/- primary lung fibroblasts did undergo 
immortalization after several rounds of passaging. Unexpectedly, we observed that 
Bmal1-/- primary lung fibroblasts showed a tendency to immortalize at earlier 
passages compare to WT (average number of passages for before immortalization 
for wild type 14.5+ 1.5 compared to 11.4 + 1.5 for Bmal1-/-) (Figure 12B).Thus, 
unlike other models of aging, Bmal1 deficiency does not result in premature 
replicative senescence of primary fibroblasts in culture and different mechanisms 
might be responsible for accumulation of senescent cells in Bmal1-/- organs.  
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A. 
              
B. 
                       
Figure 12 : Bmal1 deficiency does not affect replicative senescence in vitro.            
Lungs tissues were cut and placed in media to isolate primary fibroblasts. During 
every passage cells were counted and plated at equal density on the indicated 
days. (A) Cellular proliferation curves of primary lung fibroblasts for WT (indicated 
by closed circles) and Bmal1-/- (indicated by open circles WT and Bmal1-/- 
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proliferation curves show no difference in the onset of replicative senescence, as 
observed at later passages). Results are plotted as mean + std. deviation (n= 16 
8WT, 8KO). 
 (B) Immortalization of primary lung fibroblasts from WT and Bmal1-/- mice. As 
indicated in the figure, Bmal1-/- primary lung fibroblasts showed tendency to 
immortalize at earlier passages compare to WT (average number of passages for 
before immortalization for wild type 14.5+ 1.5 and 11.4 + 1.5 for Bmal1-/- cells). 
Results are plotted as mean + std. deviation (n= 16 8WT, 8KO). 
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3. A.3 Bmal1 deficiency results in increased sensitivity to oxidative stress in 
vitro    
  The role of replicative senescence in accumulation of senescent cells in 
vivo is unclear. Stress-induced senescence might be a contributor. It can be 
induced by challenging cells with different stimuli such as DNA damage, Oncogene 
activation or aberrant mitogenic signals. Oxidative stress has been suggested as 
major contributor to stress-induced senescence. Previously, our lab has shown 
that BMAL1 is involved in Reactive oxygen species (ROS) homeostasis and life-
long treatment with antioxidant significantly increased the average and maximal 
life span of Bmal1-/- mice. Based on these data, next we hypothesized that BMAL1 
deficiency would result in increased sensitivity to oxidative stress. To test this 
hypothesis, we used hydrogen peroxide as an oxidative stress inducer.  
Immortalized WT and Bmal1-/- lung fibroblasts were plated at equal density in 
three 96 well plates. After 24 hours of plating, cells were treated with regular media 
or media with different concentrations of hydrogen peroxide for 24, 48 and 72 
hours (Figure 13 from Khapre R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9). 
As expected, Bmal1-/- fibroblasts showed increased sensitivity to hydrogen 
peroxide indicated by a decreased number of cells after treatment, as detected 
using crystal violet. These results supported our hypothesis that BMAL1 is involved 
in the oxidative stress response.                            
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Figure 13 : Bmal1 deficiency results in increased sensitivity to oxidative 
stress 
Cells were plated at an equal density and treated with different concentrations of 
hydrogen peroxide for A) 24 B) 48 and c) 72 hours. The figure above shows 
survival curves for WT (closed circles) and Bmal1-/- (open Circles) fibroblasts at 
different concentrations of hydrogen peroxide. Survival of untreated cells were set 
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to 100%. Bmal1-/- cells were significantly more sensitive than WT cells. (*) P < 
0.05. Results are plotted as mean + std. deviation (n= 5). 
24 hours    WT IC50 = 450 µM        Bmal1-/- IC50 = 385 µM (A) 
48 hours    WT IC50 = 200 µM        Bmal1-/- IC50 = 140 µM (B) 
72 hours    WT IC50 = 150 µM        Bmal1-/- IC50 = 87.5 µM (C) 
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3. A.4 Bmal1 deficient cells are more sensitive to oxidative stress-induced 
growth arrest 
After determining that Bmal1-/- cells are more sensitive to oxidative stress, 
indicated by a decreased number of cells present after hydrogen peroxide 
treatment, next we wanted to investigate the effect of oxidative stress on Bmal1-/- 
cells. Oxidative stress can either induce cell arrest or cell death, so the next step 
was to investigate if the increased sensitivity of Bmal1-/- cells was due to increased 
cell death or reduced proliferation. For both experiments WT and Bmal1-/- 
immortalized lung fibroblasts were used. To examine the effect of oxidative stress 
on cell death, we used CytoTox-ONE™ Homogeneous Membrane Integrity Assay 
(Promega) as per manufacturer’s instructions. Cells were plated at an equal 
density in 96-well plates and treated with different concentrations of hydrogen 
peroxide.  At different time points, cells were fixed and treated with cell death kit 
reagents for assay. Fluorescence was measured using a Victor Wallac counter.  
To examine the effect of oxidative stress on cell proliferation, we performed 
colony forming assay, following a concentration of hydrogen peroxide at which the 
difference in sensitivity to oxidative stress was maximum. Cells were plated at an 
equal density and treated with either regular media or 250 µM hydrogen peroxide 
for 96 hours or treated with hydrogen peroxide for 24 hours and then in regular 
media for an additional 72 hours. Cells were fixed and stained with crystal violet 
and formed colonies were counted. 
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After hydrogen peroxide treatment, we did not observe any significant difference 
in the rate of cell death between WT and Bmal1-/- cells (Figure 4A Figure from 
Khapre R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9.) 
In a cell proliferation assay, there was no difference in the number of 
colonies for untreated cells. Hydrogen peroxide treatment resulted in reduced 
number of colonies in WT and Bmal1-/- cells but the effect was significantly 
stronger in Bmal1-/- cells (Figure 4B Figure from Khapre R V et al. Cell cycle. 2011 
Dec 1; 10 (23):4162-9). We also observed that reduction in number of colonies after 
hydrogen peroxide treatment was not as dramatic as reduction in colony size This 
indicated that oxidative stress induced growth arrest was stronger in Bmal1-/- cells. 
This was also supported by another observation that when cells were treated for 
24 hours with hydrogen peroxide and then allowed to grow for additional 72 hours 
in regular media, no difference between genotypes was observed (Figure 14C 
Figure from Khapre R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9).  
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Figure 14 : Bmal1 deficient cells are more sensitive to oxidative stress 
induced growth arrest.  
(A) Cell death curves for WT (closed circles) and Bmal1-/- (open circles) fibroblasts 
plated at an equal density and after treatment with different concentrations of 
hydrogen peroxide. With increase in hydrogen peroxide concentration, there was 
increase in cell death but no difference was observed between WT and Bmal1-/- 
cells. (B) The number of colonies formed by WT (black bars) and Bmal1-/- gray 
bars) immortalized lung fibroblasts. Cells were plated at equal density and treated 
with  regular media (U/T) for 96 hours or in presence of 250 µM of hydrogen 
peroxide (H2O2) or treated with 250 µM hydrogen peroxide for 24 hours and then 
in regular media for additional 72 hours (250 µM H2O2/media.(C) Representative 
Images of Colony Forming assay. Colonies were stained with crystal violet and 
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excess dye was washed out with water. These curves are average of 4 
independent experiments plotted as mean + std. deviation. 
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3. A.5 Differential effect of Bmal1 deficiency on cell sensitivity to anti-cancer 
drugs. 
After determining that Bmal1-/- cells are more sensitive to hydrogen 
peroxide treatment, next we wanted to investigate if the observed increased 
sensitivity of Bmal1-/- cells to hydrogen peroxide treatment is specific to oxidative 
stress or is a consequence of changes in genotoxic stress resistance. To explore 
the role of Bmal1 deficiency in general genotoxic stress, we compared resistance 
of WT and Bmal1-/- lung immortalized fibroblasts to different anticancer drugs. 
These drugs were selected in such a way that they act through different pathways 
and affect cell proliferation, cell death through different mechanisms. Assays were 
performed in similar way as mentioned for hydrogen peroxide.  
The different anticancer drugs showed a different effect on Bmal1-/- cells. 
Paclitaxel (Taxol) is a microtubule stabilizing drug. Microtubules are tubular 
polymers of α and β tubulin dimers.  Paclitaxel binds to β-tubulin polymer and 
stabilizes microtubules by disturbing the steady state equilibrium between tubulin 
dimers and microtubules. These result in changes in dynamicity of microtubules, 
mitotic cell arrest, and cell death. Treatment with paclitaxel did not show any 
significant difference in sensitivity of WT and Bmal1-/- cells (Figure 15A from 
Khapre R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9). Next we tested 5-fluorouracil 
which is an antimetabolite, a pyrimidine analogue that causes scarcity of thymine 
leading to cell death. Treatment with 5-fluorouracil also did not show any significant 
difference in the sensitivity of WT and Bmal1-/- cells (Figure 15B from Khapre R 
V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9). Treatment with Daunorubicin 
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(antimitotic activity) also showed similar results. Bmal1-/- cells were more resistant 
to Daunorubicin than WT (WT IC50 = 45.35 nM, Bmal1-/-, IC50 = 95.5 nM). (*) P 
< 0.05 (Figure 15C from Khapre R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-
9). We also tested Etoposide (topoisomerase ΙΙ inhibitor). This assay showed that 
Bmal1-/- cells were more resistant to Etoposide compare with WT. (WT IC50 = 
56.33 ng/ml, Bmal1-/- IC50 = 110.9 ng/ml) (*) P < 0.05 (Figure 15D from Khapre 
R V et al. Cell cycle. 2011 Dec 1; 10 (23):4162-9). These results indicated that 
Bmal1 deficiency does not change sensitivity to all drugs. Bmal1-/- deficiency did 
not affect cell sensitivity to Paclitaxel and 5-fluorouracil but made cells more 
resistant to other drugs such as Etoposide and Daunorubicin. 
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Figure 15 : Bmal1 deficient cells have different sensitivity to anticancer 
drugs. 
Relative survival curves of WT and Bmal1-/- immortalized lung fibroblasts plated 
at equal densities and treated with different concentrations of (A) Paclitaxel, (B) 
Daunorubicin, (C) 5-fluorouracil, (D) Etoposide. Survival of untreated cells was set 
to 100%.The curves are average of 3 independent experiments.  As shown in (A) 
and (B), Bmal1-/- cells did not show any significant difference in sensitivity to 
paclitaxel and 5-Flurouracil when compared with WT. But, Bmal1-/- cells showed 
higher resistance to Etoposide WT IC50 = 56.33 ng/ml, Bmal1-/- IC50 = 110.9 
ng/ml (C) and Daunorubicin WT IC50 = 45.35 nM, Bmal1-/-, IC50 = 95.5 nM) (D) 
compared to WT. *p< 0.01. Results are plotted as mean + std. deviation (n= 5). 
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3. A.6 Increased sensitivity of Bmal1-deficient cells to oxidative stress is 
independent of p53. 
Recently, the connection between circadian clock and p53 pathways was 
established. It was also reported that downregulation of BMAL1 results in impaired 
p53-dependent DNA damage response (144). Interestingly, as shown before our 
Bmal1-/- cells show enhanced resistance to DNA damaging agents such as 
Etoposide and Daunorubicin but more sensitivity to hydrogen peroxide. One of the 
possible mechanism for this difference in that the cell sensitivity could be effect of 
interference with p53 pathway. Therefore, we investigated the role of p53 in 
BMAL1-dependent response to oxidative stress. For this purpose, mouse 
embryonic fibroblasts overexpressing GSE56 (dominant negative fragment of p53 
and can efficiently suppress p53 activity in different cell types) were used. WT 
GSE56 and Bmal1-/- GSE 56 were treated with hydrogen peroxide referring similar 
protocol similar to what was used before for lung fibroblasts. 
Consistent with data from lung fibroblasts, Bmal1-/- GSE 56 cells were more 
sensitive to hydrogen peroxide–induced oxidative stress, compared with WT 
MEF56. This result indicates that suppression of p53 did not affect the difference 
in sensitivity to hydrogen peroxide between WT and Bmal1-/- cells. From this 
experiment, we concluded that increased sensitivity to oxidative stress in Bma1-/- 
cells is independent of p53 (Figure16 from Khapre R V et al. Cell cycle. 2011 Dec 1; 10 
(23):4162-9). 
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Figure 16 : Increased sensitivity of Bmal1 deficient cells to hydrogen 
peroxide is independent of p53. 
WT GSE56 and Bmal1-/- GSE56 cells were plated at equal densities and treated 
with different concentrations of hydrogen peroxide for 72 hours. Cells were washed 
and fixed with 0.2% glutaraldehyde and stained with 0.05% crystal violet. The dye 
was extracted using 1% SDS and absorbance was measured at 570 nM. The 
absorbance value corresponds to the number of cells stained for each plate. The 
relative survival curve of GSE56 (dominant negative fragment of p53) WT (black 
circles) and BMAL1-/-(open circles) fibroblasts showed higher sensitivity of Bmal1 
-/-cells to hydrogen peroxide compared with WT. Survival of untreated cells was 
set to 100%. (*) indicates p<0.01. Results are plotted as average of 3 independent 
experiments. 
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 3. B. Circadian regulation of mTOR signaling pathway through BMAL1 
dependent mechanism.  
3. B.1 Cellular consequences of increased mTORC1 signaling due to Bmal1 
deficiency. 
When we were passaging with WT and Bmal1-/- primary lung fibroblasts, 
we made unexpected results. Based on our senescence-associated β-Gal staining 
with tissues, we expected that Bmal1-/- primary fibroblasts would undergo 
senescence at earlier passages in comparison with WT. To our surprise, we did 
not observe any difference in the onset of replicative senescence between WT and 
Bmal1-/- cells. On the contrary, we observed that Bmal1-/- cells immortalized at 
earlier passages compare to WT. We also observed that the immortalized Bmal1-
/- fibroblasts proliferated at a significantly higher rate (Figure 17 from Khapre R V 
et al. Aging (Albany NY). 2014 Jan; 6(1):48-57). 
We decided to investigate further on increased proliferation of Bmal1-/- 
immortalized cells. We also measured cell size and protein content in these Bmal1-
/- cells. Cell size was measured by FACS wherein Bmal1-/- cells showed bigger 
cell size relative to WT (Figure 18 from Khapre R V et al. Aging (Albany NY). 2014 
Jan; 6(1):48-57). For measuring protein content, we used the Bradford assay. 
Immortalized lung fibroblasts were plated at an equal densities. After 6 hours of 
plating, cells were collected in PBS, counted and Bradford assay was performed 
using Coomasie blue (BIO-RAD) as per manufacturer’s protocol. Bmal1-/- cells 
always showed higher protein concentration compared with an equal number of 
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WT cells (Figure 19 from Khapre R V et al. Aging (Albany NY). 2014 Jan; 6(1):48-
57). 
The mTORC1 signaling pathway is an evolutionarily conserved pathway 
which acts as a sensor for nutrients, energy and growth factors for cells. 
Depending on the availability of these nutrients, it regulates various cellular 
processes such as cell growth, cell proliferation and metabolism. It has been 
shown that inhibition of mTORC1 pathway extends lifespan in many model 
organisms and confers protection against many age related pathologies. Recently, 
a role for the mTORC1 pathway in cellular senescence has been established. We 
found that Bmal1-/- cells demonstrate characteristics of increased activity of 
mTORC1 signaling such as increased cell proliferation, cell size and protein 
content. 
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Figure 17 : Bmal1 deficiency results in increased cell proliferation of lung 
fibroblasts. 
Cell proliferation curves for WT and Bmal1-/- fibroblasts plated at equal density 
from 1 to 5 days in culture. Proliferation curve shows that after the second day of 
plating, Bmal1-/- cells start proliferating at significantly higher rate compared with 
WT, as indicated by the higher cell number. (*) p < 0.05. Results are plotted as 
mean + std. deviation (n= 4 for each time point for both genotypes). 
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Figure 18 : Bmal1 deficiency results in increase in cell size. 
Cell size for immortalized WT and Bmal1-/- fibroblasts. As detected by FACS 
Bmal1-/- fibroblasts (grey Bar) shows significantly larger cell size compare with WT 
(Black Bar) (*) p < 0.05.  
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Figure 19 :  Bmal1 deficiency results in increased cellular protein content 
Representative graph of protein content per WT (Black bar) and Bmal1-/- fibroblast 
(grey bar) measured by Bradford reagent. As shown Bmal1-/- fibroblast has 
significantly higher amount of protein in comparison with WT. (*) p < 0.05 Results 
are plotted as mean + std. deviation from average of 3 independent experiments 
(n= 3 for both genotypes). 
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3. B.2 increased mTORC1 signaling results in increased cell proliferation, 
which is sensitive to mTORC1 inhibitor Rapamycin. 
Since we know that Bmal1-/- cells show higher rate of proliferation, first we 
wanted to determine if this increased proliferation is a result of increased mTORC1 
activity. If Bmal1-/- cells have increased mTORC1 activity, which leads to 
increased proliferation, then inhibition of mTORC1 activity should diminish the 
increased cell proliferation in Bmal1-/- cells. We used a well-known mTORC1 
inhibitor, Rapamycin to inhibit its activity. Rapamycin is a bacterial antimetabolite 
and has antifungal activity. It binds to FKBP12 (FK506 binding protein) and this 
complex interacts physically with mTOR and inhibits mTORC1 activity. mTORC1 
inhibition results in inhibition of cell proliferation.  
For the cell proliferation experiment, cells were plated at an equal density 
in 96- well plates and treated with different concentrations of Rapamycin. 
Untreated Bmal1-/- cells proliferated at significantly higher rate compared with WT. 
Rapamycin treatment eliminated this difference (Figure 20 from Khapre R V et al. 
Aging (Albany NY) 2014 Jan; 6(1):48-57). This indicates that increased 
proliferation of Bmal1-/-cells is a result of increased mTORC1 activity. 
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Figure 20: Increased proliferation of Bmal1 deficient cells is sensitive to 
Rapamycin. 
Cell proliferation curves for WT(black line) and Bmal1-/- (grey line) fibroblasts 
plated at equal density and  treated with media with indicated concentrations of  
Rapamycin for 72hr. Cell biomass was assayed by crystal violet incorporation. 
Proliferation curve indicates that Bmal1-/- fibroblasts are more sensitive to 
Rapamycin treatment. Data represent mean and standard deviation for 4 
replicates. (*) indicates p < 0.05.  
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3. B.3 Increased mTORC1 signaling results in increased phosphorylation of 
mTOR downstream targets in Bmal1 deficient immortalized lung fibroblasts 
and phosphorylation is sensitive to Rapamycin. 
It is known that mTORC1 exerts its effects via activation of its downstream 
targets. mTOR is a serine/threonine protein kinase and it activates its downstream 
targets by phosphorylation. mTORC1 activity is measured by phosphorylation of 
its downstream targets. Though many mTORC1 targets are known, S6K1 (p70) is 
the best studied and commonly used target for mTORC1 activity. S6K1 is a direct 
target of and is phosphorylated by mTORC1 at a specific site T389. Ribosomal 
protein S6 is a direct target of S6K1 and is phosphorylated by S6K1 at four 
conserved residues (S235, S236, S240, and S244).Phosphorylation of ribosomal 
protein S6 is also a commonly used marker for mTORC1 activity. After observing 
the effect of Rapamycin on cell proliferation, we wanted to examine it at the 
molecular level. Therefore, we decided to determine phosphorylation of mTOR 
targets in WT and Bmal1-/- cells after Rapamycin treatment. We performed 
western blotting analysis to check expression of phosphorylated and total S6. 
Phosphorylation was detected using specific antibodies. As expected, we found 
that Bmal1-/- cells showed increased phosphorylation of S6 while total protein 
levels were similar in WT and Bmal1-/- cells. The increased phosphorylation of S6 
in Bmal1-/- cells was sensitive to Rapamycin, indicating a higher mTOR activity in 
Bmal1-/- cells (Figure 21 from Khapre R V et al. Aging (Albany NY). 2014 Jan; 
6(1):48-57).  
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Figure 21 : Increased phosphorylation of mTORC1 targets in Bmal1 deficient 
cells is sensitive to Rapamycin. 
Immortalized WT and Bmal1-/- cells were plated at equal density and either 
untreated (U/T) or treated with  5,10, and 20 nM Rapamycin for 24 hours  and 
western blotting was performed  with cell lysates using phosphorylated and protein 
specific antibodies. β-actin was used as a loading control to ensure equal loading. 
The above experiment is representative of two independent experiments.  
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3. B.4 Increased mTORC1 signaling results in increased phosphorylation of 
mTORC1 downstream targets in primary Bmal1 deficient lung fibroblasts.  
After confirming increased mTORC1 activity in immortalized Bmal1-/-
fibroblasts, next we wanted to determine if we can detect increased mTORC1 
activity in primary lung fibroblasts. We performed western blotting analysis on WT 
and Bmal1-/- lung fibroblasts for mTORC1 targets.  We used 2 WT and 3 Bmal1-
/- primary lung fibroblasts isolated from different mice. Each WT and Bmal1-/- line 
represents individual clone (Figure 22 from Khapre R V et al. Aging (Albany NY). 
2014 Jan; 6(1):48-57). Western blotting of different primary cells representing 
individual clone confirmed that mTOR activity is increased in all Bmal1-/- cells and 
is not limited to one specific clone. Twenty four hours before lysate collection, cells 
were incubated in either regular media or media with no serum. The no serum 
condition was used as a negative control because in the absence of nutrients or 
serum, the mTORC1 pathway is not activated, which can be observed by the low 
levels of phosphorylation of mTORC1 targets. We observed similar results in the 
western blot analysis.  
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Figure 22 : Bmal1-deficient primary lung fibroblasts show high mTORC1 
activity. 
Western blotting of WT (WT-2T, WT-1F) and Bmal1-/- (KO-2T, KO-2L, KO-1F) 
primary lung fibroblasts incubated in media with (+) or without (-) 10% FBS using 
specific antibodies. Bmal1-/- cells show increased phosphorylation of S6K1 and 
S6 when compared with WT cells with no significant change in total protein levels. 
Treatment with 5, 10 and 20 nM Rapamycin for 24 hours resulted in decreased 
phosphorylation indicating high mTOR activity. B-actin was used as a loading 
control. The above result is representative of two independent experiments.  
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3. B.5 Liver tissues show oscillation in phosphorylation of mTORC1 targets 
over a period of 24 hours. 
Having determined that Bmal1 deficiency results in increased mTORC1 
signaling in primary and immortalized lung fibroblasts supported our hypothesis 
that mTORC1 signaling is under circadian clock control.  Next, we wanted to 
examine if we can observe similar relationship in vivo. If mTORC1 signaling is 
under circadian clock control, we expected that we should observe circadian 
rhythms in activation of mTORC1 signaling in tissues. To test this, we performed 
Western blotting analysis on different tissues collected from WT mice in period of 
24 hr (Circadian profile). 
 For this purpose, we selected organs which are known to be under 
circadian clock control and are also reported to show robust mTORC1 activity. All 
tissues were collected over a 24 hr period starting at ZT2 (2 hours after lights were 
switched on) at 3 hours interval. All tissues were stored at -80˚C after collection. 
Lysates were prepared using sonication as described in material and methods and 
western blot was performed using phosphor-specific and protein- specific 
antibodies (Figure 23).As expected we observed that WT mice show oscillation in 
phosphorylation of mTORC1 targets namely S6K1 (T389), ribosomal protein S6 
(S234, S235, S240, S244) and 4EBP1 (T37,T46) with no rhythms in total protein 
expression levels.   
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Figure 23 : mTORC1 signaling shows oscillations in activation over a period 
of 24 hour in liver. 
Western blotting of liver of WT mice collected over 24 hours (ZT2 to ZT23) at 3 
hours interval. Lysates were prepared by sonicating tissues in Cell Signaling 
Buffer. Blots were incubated with specific primary antibodies as shown in figure. 
β-actin was used as a loading control. Liver tissue shows oscillation in the 
phosphorylation of S6K1, S6, and 4EBP1 without significant changes in total 
protein levels.  
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3. B.6 Heart tissues show oscillation in phosphorylation of mTORC1 targets 
over a period of 24 hours. 
After having determined that liver shows oscillation in mTOR activity, next we 
wanted to determine if this effect is specific to liver or can be detected in other 
tissues. Next we decided to mTOR activity in the heart, another organ which is 
very well known to be under circadian control. For this purpose, we collected 
tissues in similar way as described for liver. Western blot analysis was performed 
using specific antibodies for the mTORC1 signaling pathway  As indicated in figure, 
heart did show rhythmic activation of mTORC1 signaling but it is not as robust as 
liver, indicating tissue variability (Figure 24). 
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Figure 24 : mTORC1 signaling shows oscillations in activation over a period 
of 24 hours in the heart. 
Western blotting of heart tissues of WT mice collected over 24 hours (ZT2 to ZT23) 
at a 3 hours interval. mTORC1 downstream targets were detected using antibodies 
recognizing the indicated proteins (total or phosphorylated). Heart shows 
oscillation in the phosphorylation of S6K1, S6, 4EBP1 without significant changes 
in total protein levels. GAPDH was used as a loading control.  
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3.B.7 Spleen show oscillation in phoshorylation of mTORC1 targets over 
period of 24 hours. 
We also determined rhythms in activation of mTORC1 signaling in the spleen. 
Tissues were collected as described for liver and heart. We observed a similar 
pattern of rhythms in  spleen (Figure 25). 
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Figure 25 : mTORC1 signaling shows oscillations in activation over a period 
of 24 hours in spleen tissue. 
Western blotting of spleen tissues of WT mice collected over 24 hours (ZT2 to 
ZT23) with 3 hours interval. β-actin was used as loading control. As shown in 
figure, spleen shows oscillation in the phosphorylation of p70, S6, 4EBP1 without 
significant changes in total protein levels.  
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3. B.8 Daily rhythms in activation of mTORC1 signaling in liver under time 
restricted feeding regimen. 
mTORC1 signaling pathway is a nutrient sensing pathway and food intake  results 
in its activation. Since liver is the central organ for metabolism, mTORC1 activity 
in liver can be significantly affected by food. For all our above experiments food 
was available all the time (Ad libitum) to animals and it is possible that the 
oscillations in activation of mTOR were result of different eating habits of individual 
animals.  
To confirm our hypothesis that mTORC1 signaling is under control of circadian 
clock, we changed the feeding regimen for mice from Ad Libitum to time restricted 
feeding (tRF) regimen. In time restricted feeding, 95-100% of their daily intake 
consumption was provided at ZT14 (approximate time when mice wake up) and 
no food was provided for next 24 hours. We observed that the total amount of food 
provided was consumed within the first 3-4 hours. All mice were kept with tRF for 
a 2 weeks regimen before collection of tissues. We also analyzed daily in cage 
activity of these mice to check effect of changed food regimen on their behavior. 
We found no difference in the behavior for these mice when kept on Ad libitum or 
time-restricted feeding regimen. Tissues were collected as described before and 
stored at -80˚C. Lysates were prepared as per previous protocol and western blot 
analysis was performed. As expected, after food was provided at ZT14 we 
observed a gradual increase in phosphorylation of S6K1 at T389, which reached 
maximum at ZT22 and then decreased gradually.  We also observed a similar 
pattern in phosphorylation of 4EBP1 with delayed onset indicating different 
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regulation of S6K1 and 4EBP1 by mTORC1. Rhythms in phosphorylation were 
consistent even for S6. Interestingly at ZT10 and ZT14 when no food was 
available, we observed an increase in phosphorylation of S6K1 at T389 indicating 
anticipation of food (Figure 26). 
We observed that liver tissues from animals with a time-restricted feeding regimen 
showed oscillations in mTORC1 activation, as observed with Ad Libitum mice. 
These oscillations were even more robust and clear compared with Ad Libitum 
indicating a masking effect of food in Ad Libitum and that effect is eliminated in 
time-restricted feeding. Increased phosphorylation of mTORC1 targets at the time 
of food availability indicates activation of mTORC1 signaling. 
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Figure 26 :  time restricted feeding demonstrates clear rhythms in 
activation of mTORC1 signaling in the liver tissue. 
Western blot of liver tissues collected from WT mice fed at ZT 14 with 100% of 
daily food intake. Tissues were collected over 24 hours starting at ZT14 with 4 
hours interval. At ZT 14 phosphorylation of S6K1 at T389 started to increase until 
ZT 22 and then decreased as indicated by low levels at ZT 2 and ZT6. At ZT14 
even though food was not provided, phosphorylation of S6K1 at T389 showed an 
increase, indicating anticipation of food. β-actin was used as loading control. 
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3. B.9 Daily rhythms in activation of mTORC1 signaling in liver are 
endogenous and independent of food. 
Once we confirmed that under tRF regimen mTORC1 displays rhythmic activation, 
next we wanted to check if this rhythmicity is endogenous and can be sustained 
independent of food. For this purpose, we used 52 hours fasting conditions for 
animals. For fasting experiments, the same amount of food as tRF was provided 
at ZT14 and then no food was provided for the next 2 feeding cycles (48 hours). 
Tissues were collected and stored as described before. Western blot analysis was 
performed as described earlier. We observed that both S6K1phosphorylation sites, 
T421/S424 and T389 show rhythms, but they were in different phases.T421/S424 
is not mTORC1 specific phosphorylation site and is known to be activated by 
MAPK. But T389, mTORC1 specific phosphorylation site showed activation at 
ZT14-ZT22 periodically starting from 1hr, 24hrs, and 48hrs after the food was 
provided. 4EBP1 phosphorylation also showed similar pattern of rhythms but with 
delayed onset occurring at ZT18 (4 hr after food was provided) and repeated every 
24 hr (Figure 27).  Even when no food was provided at time points when it was 
expected such as at time points 24 hr and 48 hr, we observed increased 
phosphorylation of S6K1 at T389, indicating anticipation of food. It shows that 
rhythmic activation of mTORC1 signaling is endogenous and independent of food. 
This result supported our hypothesis that mTOR pathway shows endogenous 
oscillations in activation. These oscillations in mTOR activation are independent of 
food and nutrients and are probably driven by circadian clock.   
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Figure 27 : Oscillations in activation of mTORC1 signaling in liver tissues are 
endogenous and independent of food. 
A. Western blotting for mTORC1 downstream targets in WT liver. At 0 hr, 24 hr, 
48 hr after food was provided At 24 and 48 hr, phosphorylation at T389 was 
increased even when no food was provided. 4EBP1 also shows similar pattern of 
phosphorylation but with delayed onset. No significant changes in total protein 
levels were observed. GAPDH was used as loading control. B. Quantification 
shows circadian oscillations in phosphorylation of S6K1, S6 and 4EBP1. Peaks 
marked with red asterisks indicate maximum phosphorylation. For S6K1, 
phosphorylation at T389 (mTORC1specific site) shows 3 asterisks at  0hr,24 hr 
and 48 hr indicating oscillations in phosphorylation with  periodicity of 24 hrs. 
Phosphorylation at T421/S424 does show a 24 hr periodicity but is in anti-phase 
with T389. 4EBP1 also shows 2 peaks in phosphorylation that are delayed 
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compared to S6K1 and occurring with a periodicity of 24 hr. Data represent mean 
and standard deviation for 3 replicates (*) p < 0.05. 
  
100 
3. B.10 Bmal1 deficiency (disruption of circadian clock) results in increased 
mTORC1 signaling and change in phase of activation of mTORC1 in vivo. 
Having determined that Bmal1 deficiency results in increased mTORC1 signaling 
in primary and immortalized lung fibroblasts and different tissues showed 
oscillations in activation of mTORC1 signaling, we next hypothesized that Bmal1 
deficiency would result in alteration in mTORC1 activity in different tissues. The 
alternation could be a change in level of phosphorylation, change in phase of 
activation of downstream targets or change in amplitude of oscillation. We also 
hypothesized that tissues which are known to be under circadian clock control will 
be affected most by Bmal1 deficiency. To test this hypothesis, we decided to 
perform western blotting analysis on liver tissue from BMAL1 KO mice. We 
checked mTORC1 signaling in BMAL1 deficient mice kept on time restricted 
feeding regimen. We followed a similar food regimen as in the WT mice used 
before. 
As expected, we observed non-rhythmic phosphorylation of mTORC1 targets 
S6K1 (T389) and 4EBP1 (T37/46) indicating an effect of Bmal1 deficiency on 
regulation of mTORC1 signaling. In addition we also observed significantly 
increased phosphorylation of S6K1 at T389 for many time points, indicating a 
continuous activation of mTOCR1 signaling. Phosphorylation at T421/S424 (non 
mTOR specific site) on S6K1 did not show significant change in oscillations or in 
level of phosphorylation, indicating Bmal1 deficiency results in deregulation of 
mTORC1 signaling specifically (Figure 28). It results in constitutive activation of 
mTORC1 signaling in BMAL1-deficient mice, supporting our hypothesis that the 
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circadian clock negatively regulate mTORC1 signaling through a BMAL1- 
dependent mechanism.      
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Figure 28 : Bmal1 deficiency results in non-rhythmic activation of mTORC1 
signaling in liver. 
A. Western blot of liver tissues collected from BMAL1 mice over 40 hours starting 
at ZT14 with 4 hours interval. Blots were incubated with specific primary antibodies 
as shown. B-actin was used as loading control. Bmal1-/- mice show nonrhythmic 
oscillations in the phosphorylation of S6K1 at T389 (mTOR site) which is 
constitutively active at almost all time points. In contrast, phosphorylation at 
T421/S424 (non mTOR site) does not show significant difference in oscillations 
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and level of phosphorylation. 4EBP1 also shows disrupted pattern of 
phosphorylation in BMAL1 deficient mice. 
Quantification of phosphorylation of S6K1 (T389), 4EBP1 (T37/46) and S6K1 
(T421/S424) in WT (Black line) and BMAL1 KO (Grey line) liver. Data represent 
mean and standard deviation for 4 replicates. (*) p < 0.05 Figure from Khapre R V 
et al. Aging (Albany NY). 2014 Jan; 6(1):48-57 
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3. B.11 Regulation of mTORC1 signaling at mRNA level by BMAL1 as 
transcription factor. 
Finally, in an effort to determine, how the circadian clock, especially BMAL1 
regulates mTORC1 signaling, we used quantitative PCR approach. Considering 
that BMAL1 is a transcription factor, we expected to observe regulation at mRNA 
level. mTORC1 signaling is regulated either at upstream (activators and inhibitors) 
level or at mTORC1 complex level (different components of the complex). 
Therefore, we decided to check mRNA expression of mTOR complex and mTOR 
pathways genes. We found that expression of tor and deptor mRNA was highly 
affected by Bmal1 deficiency. In support of our hypothesis that circadian clock 
negatively regulates mTORC1 signaling, we observed that expression of tor was 
significantly upregulated at several time points (Figure 29a), while expression of 
deptor (negative regulator of mTOR) was significantly downregulated at several 
time points (Figure 29b) in the liver of Bmal1-/- mice.                                                                      
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Figure 29 : mRNA expression of mtor and deptor in liver from WT and 
BMAL1 KO mice.  
The mRNA expression of tor (a) and deptor (b), in liver of tRF WT ((black 
diamonds) and BMAL1 KO (grey squares) mice were analyzed over a daily cycle 
(24 hours) by real-time RT PCR. All data was normalized to 18s ribosomal RNA 
expression.  Bars on top of the figure represent the light (open bars) and dark 
(black bars) part of the day. Data represent mean and standard deviation for 3 
replicates. P < 0.05. (*) Statistically significant difference.  
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CHAPTER IV 
DISCUSSION 
 
 
4.1 Overview 
Over the last century, through progression in drug development, 
improvement in living conditions and increased health awareness, human life 
expectancy has increased dramatically. As a result, a substantial percentage of 
population lives significantly longer than in the past. With increasing human 
lifespan, we have to cope with growing problems and difficulties due to age related 
pathologies. These pathological conditions not only affect the quality of life but also 
affects economic status. Therefore, elucidation of mechanisms involved in age 
related pathologies are becoming extremely important with eventual goal of 
developing effective and preventive therapies. 
For centuries, humans have been looking for ways to avoid aging, which gave rise 
to a foundational need for understanding the process of aging. Albeit several 
proposed theories, the mechanisms of aging are not well understood. As inevitable 
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as it is, aging is a complex process and can be defined in many ways. In simple 
terms, it involves deterioration of biological systems with reduced fitness and over 
all well-being of living organisms. It can also be seen as a risk factor for causing 
new diseases or consequence of many diseases.  
Development of various aging models has made remarkable progress in the field. 
Our lab is also working with one of the models of premature aging in mice. This 
model represents disrupted circadian clock due to deficiency of core circadian 
clock protein BMAL1. The circadian clock is an endogenous time keeping system 
in organisms which helps them synchronize their physiology and behavior with 
environmental changes surrounding them such as day-night cycle.  Circadian clock 
creates rhythms in various physiological processes. In mammals, it is represented 
by an autoregulatory negative feedback loop of core clock proteins. BMAL1 and 
CLOCK are transcription factors which heterodimerize and bind to E- box elements 
in promoter region of many genes to drive their expression.  Circadian clock also 
drives expression of genes which are not part of the loop but their rhythmic 
expressions are important for physiological outputs (1, 2, 3) 
The area of circadian clock has been explored for over 45 years. It was 
discovered that administration of mutagenic substance in fruit flies resulted in 3 
mutants with different circadian cycles (142). After 25 years of the first discovery, 
the first mammalian circadian clock gene CLOCK was discovered in mice leading 
to discovery of other core clock genes required for circadian rhythms. In recent 
years, extensive research in circadian clock field has linked it to many sleep, 
neurological, cardiovascular, and metabolic disorders (17,35). Even certain types 
109 
of cancer have been linked to disruption of circadian clock. It was demonstrated in 
various studies that shift workers (clock is disrupted) have higher risk of developing 
cardiovascular, metabolic, neurological disorders and cancer. Considering 
noteworthy percentage of world’s population works in shifts, study of disrupted 
circadian clock is getting even more emphasis especially to identify role of clock 
proteins in aging and age related pathologies. Various animal models of disrupted 
circadian clock are available which exhibit conditions that are related to different 
aging pathologies.  
Our lab focus has been deeply invested to determine molecular 
mechanisms involved in premature aging in BMAL1 (core Clock component) 
deficient mice. BMAL1 is the only known circadian clock component, which in 
deficiency, causes complete arrhythmicity in constant darkness in mice. Our lab 
has previously demonstrated that Bmal1-/- mice display reduced lifespan. They 
also develop many age related pathologies such as cataract, memory loss, 
sarcopenia and infertility prematurely. Our lab has previously shown that BMAL1 
plays a significant role in Reactive Oxygen Species (ROS) homeostasis. Bmal1 
deficient mice displayed increased accumulation of ROS in different organs such 
as heart, kidney and spleen. Interestingly, similar tissues also displayed age 
dependent reduction in size. In addition to that, Bmal1-/- mice treated with 
antioxidant N-acetyl-L-cysteine through their lifespan showed increased average 
and maximum life span. Treatment with antioxidant also reduced certain age 
related pathologies such as cataract and weight loss but surprisingly had no effect 
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on many other pathologies observed in Bmal1-/- mice. This indicated that ROS 
can affect aging but ROS independent mechanisms are involved. 
It has been documented that aging is associated with increased accumulation of 
senescent cells in tissues. Senescence is a specific state of cells characterized by 
irreversible growth arrest, flat and enlarged morphology, changed gene 
expression, resistance to apoptosis and secretion of degradative enzymes which 
are believed to disrupt surrounding tissue environment and might contribute to 
aging. Senescence is categorized into 3 different types; 1) Replicative,2) Stress 
induced,3) Oncogene induced. Though senescence was first reported as 
replicative senescence in cell culture, its significance in age associated 
senescence is not clear. Conversely, other research shows that stress induced 
senescence plays a role as anticancer mechanism and can be related to 
mechanisms of aging. We further investigated role of different types of senescence 
in Bmal1 deficient mice. Interestingly tissues from Bmal1-/- mice showed 
significantly higher number of senescent cells when compared to WT mice of same 
age. These observations drove us to further investigate molecular mechanisms 
involved in role of BMAL1 in cellular senescence which contribute to aging 
observed in Bmal1-/- mice. Results presented in this dissertation present different 
mechanisms with role of BMAL1 in premature aging in mice. In this proposal, we 
identified that BMAL1 regulates oxidative stress induced senescence which is in 
correlation with our previously published data displaying disrupted ROS regulation 
in Bmal1 deficient mice. In this thesis, we demonstrated that there is no significant 
difference in replicative senescence between WT and Bmal1-/- primary fibroblasts 
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in vitro. This also indicates BMAL1 does not contribute to replicative senescence 
and also replicative senescence might not contribute to premature aging in Bmal1-
/- mice. 
Oxidative stress is a potent stress inducer and probably has role in stress 
induced senescence in vivo. We demonstrate here that BMAL1 plays a role in 
oxidative stress sensitivity and oxidative stress induced senescence. BMAL1 
deficiency results in increased oxidative stress in mice. Recent studies with shift 
workers, demonstrated increased oxidative stress measured by oxidative stress 
markers. As shift work is known to disrupt circadian clock, these results very well 
support our observations of increased oxidative stress in BMAL1 KO mice (142). 
Our results pointed to a new question if the sensitivity of Bmal1-/- cells is specific 
to oxidative stress or they are also sensitive to genotoxic stress. Role of BMAL1 in 
cell sensitivity to genotoxic stress and cell cycle is well documented (our review). 
We checked effect of BMAL1 deficiency in genotoxic stress using different DNA 
damaging agents each with different mode of action. Previous studies suggest, 
tumor cells with downregulation of Bmal1 expression with shRNA were more 
resistant to Etoposide induced apoptosis (143). In agreement with this data, we 
observed that Bmal1-/- cells show more resistance to some DNA damaging agents 
such as Etoposide or Daunorubicin. But no difference was observed with another 
DNA damaging agent named 5-flurouracil. Other research suggests that BMAL1 
interferes with p53 dependent DNA damage response (144). However, we further 
observed that role of BMAL1 in oxidative stress response was independent of p53. 
After collective analysis of this data, we revealed that BMAL1 does not play any 
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role in replicative senescence but it regulates oxidative stress induced senescence 
in vivo. Bmal1 deficiency results in accumulation of senescent cells in vivo which 
can contribute to premature aging. Our work is supported by a recently published 
work on role of Bmal1 in neuronal oxidative damage and neurodegeneration 
suggesting its role brain aging (145). 
It is well known that, senescent cells display over activation of growth 
promoting pathways such as mTORC1. mTORC1 is a nutrient sensing pathway 
involved in various cellular processes such as cell growth and proliferation. Many 
growth related processes such as nutrient uptake, protein synthesis, ribosome 
biogenesis are regulated by mTORC1. In senescent cells, though cell cycle 
progression is arrested, cell growth is not. Therefore, increased mTORC1 activity 
results in senescent phenotype such as enlarged morphology. In immortalized 
cells, where cell cycle is not arrested, increase in mTORC1 activity can result in 
increased proliferation rate. Consistent with previous data, Bmal1-/- deficient cells 
have significantly increased proliferation rate, protein content, cell size and cell 
biomass compared to WT. This hinted us for overactivation of mTORC1 in Bmal1 
deficient mice. 
mTOR acts as a sensor of nutrients and regulator of cellular processes, its 
role underlines its importance in metabolism, body homeostasis and overall well-
being of organisms. Deregulation of mTORC1 signaling is linked to various 
metabolic disorders, cancer and aging. Genetic mutations and pharmacological 
inhibition of mTORC1 signaling in various models have been shown to extend 
lifespan which suggests mTORC1 is a key regulator of aging. Though mTORC1 
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regulation under nutrients or stress conditions have been studied, its regulation 
under physiological conditions is unknown. 
In our present work, we demonstrate for the first time that mTORC1 is 
regulated by circadian clock under physiological conditions. Considering mTORC1 
is a nutrient sensor, and nutrients are available only at feeding (wake cycle) 
dictated by circadian clock, we hypothesized that mTORC1 might be controlled by 
circadian clock. This regulation can help organisms to synchronize food availability 
with anabolic processes such as protein synthesis, lipid biosynthesis which are 
under mTORC1 control. The connection between circadian clock and mTORC1 
has never been explored before. Results presented here illustrate circadian 
regulation of mTORC1 and effect of disrupted circadian clock on mTORC1 
signaling. We demonstrated that mTORC1 is rhythmically activated as confirmed 
by phosphorylation of its downstream targets. This rhythmic activation is 
independent of food suggesting presence of endogenous regulation supporting our 
hypothesis.  The next question was if mTORC1 is under circadian control, then 
how does disrupted circadian clock affects mTORC1 signaling? In Bmal1 deficient 
mice, we observed that mTORC1 activation is non rhythmic and even elevated at 
several different time points. This indicates that circadian clock negatively 
regulates mTORC1 and disruption of circadian clock results in overactivation of 
mTORC1 signaling. Thus our current data suggests that constitutively elevated 
mTORC1 signaling may result in premature aging in Bmal1 deficient mice. To test 
this hypothesis, our collaborators checked whether pharmacological suppression 
of mTORC1 by Rapamycin (potent and specific mTORC1 inhibitor) can extend 
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lifespan in Bmal1 deficient mice. Previous studies with Rapamycin to inhibit 
mTORC1 demonstrated increased life span and delayed onset of age related 
pathologies in old mice. In support with this, our collaborators demonstrated that 
lifelong treatment with Rapamycin extended lifespan of Bmal1 deficient mice. This 
work is still in progress. 
During our experiments with time restricted feeding and fasting regimen, we 
made interesting observations of differential regulation of S6K1 and 4EBP1 
phosphorylation by mTORC1.  S6K1 is phosphorylated at earlier time point (ZT14) 
when compared with 4EBP1 (ZT18). Both S6K1 and 4EBP1 function as translation 
regulators.  
Eukaryotic initiation factor 4E (eIF4E) is a mRNA 5’ cap binding protein and part 
of eukaryotic initiation factor 4F (eIF4F) complex involved in a cap dependent 
translation (146). In the absence of growth factors or nutrient signals, 
hypophoshorylated 4EBPs associate with eIF4E tightly, inhibiting assembly of 
eIF4F complex. In the presence of nutrients and growth factors, 4EBPs are 
phosphorylated by mTORC1 at multiple sites resulting in its dissociation from the 
eIF4E (110). Many targets of S6K1 like ribosomal protein S6, SKAR, mRNA 
splicing factor (147), eIF4B, which is activator of eIF4A helicase (part of eIF4F 
complex) (148), PDCD4, an inhibitor of eIF4A (149) are also part of translation 
machinery. If both S6K1 and 4EBP proteins are involved in translation, then why 
are they phosphorylated at different time points? What is the significance of this 
differential phosphorylation? Recent studies demonstrated that, eIF3-preinitiation 
complex (eIF3-PIC) acts as dynamic scaffold for S6K1 and mTOR/Raptor 
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(150,151). This binding is sensitive to growth factors and nutrient signals and 
Rapamycin. Under unstimulated conditions, inactive S6K1 is associated with eIF3-
PIC complex, whereas mTOR/Raptor binding to the complex is weak. When 
stimulated by nutrients and mitogens, mTORC1 associates with eIF3-PIC complex 
and phosphorylates S6K1 at T389. This phosphorylation at T389 results in 
dissociation of S6K1 from eIF3-PIC complex and S6K1 can phosphorylate its 
targets involved in translation present in close proximity. This is also observed in 
our experiments where phosphorylation of ribosomal protein S6 occurs later after 
phosphorylation of S6K1. The study also demonstrated the constitutive presence 
of eIF3 complex and eIF4E at the cap structure whereas, after insulin stimulation 
recruitment of eIF4G and dissociation of 4EBP1 was time dependent. This 
indicates that eIF3 might interact with eIF4E. The signal stimulated mTOR/Raptor 
association with eIF3 helps phosphorylation of 4EBP1 resulting in its dissociation 
from eIF4E. The suggested model indicates that association of S6K1 with eIF3 
might help for its early phosphorylation by mTORC1 (150,151). 
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Finally, we illustrated the mechanism of mTORC1 regulation by circadian 
clock. During our experiments, we observed that mTOR itself and DEPTOR 
(negative regulator of mTOR) show oscillation in their mRNA expressions, 
indicating transcriptional control of circadian clock which is known to be common 
mechanism for regulation of many clock controlled genes. We also propose a 
model underlying physiological significance of this regulation. During wake cycle, 
organisms are active and they engage in feeding making nutrients available. This 
activates mTORC1 inducing many anabolic processes such as protein synthesis, 
lipid biosynthesis and cellular growth. But during sleep phase of cycle, when 
organisms don not eat, it is essential to inhibit anabolic processes and encourage 
catabolic processes to break down macromolecules to make nutrients available. 
mTORC1 activates anabolism and inhibits catabolism, so by switching mTORC1 
activity to on or off we can regulate anabolic and catabolic processes. This 
manuscript presents critical role of circadian clock in switching off mTORC1 activity 
during sleep phase of daily cycle. 
Although mTORC1 is critical during development, it’s over activation could 
detrimental in adult organisms. Aging is associated with decline in Circadian 
rhythms and metabolic homeostasis. We present here negative regulation of 
mTORC1 signaling by circadian clock. Over activation of mTORC1 signaling in 
disrupted circadian clock model (BMAL1 deficient mice) can result in constitutive 
activation of anabolic processes leading to nutrient depletion, imbalance in 
homeostasis which can contribute to accelerated aging observed in Bmal1-/- mice. 
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4.2 Future directions 
Another interesting observation that we made was the increased rate of cell 
proliferation of immortalized Bmal1-/- fibroblasts. Cell proliferation is mainly 
regulated by cell cycle, a process that occurs in series of stages namely G1, S, 
G2, and M leading to cell division. Cell cycle is tightly regulated at all these stages 
by many cell cycle regulators and surveillance mechanisms known as cell cycle 
checkpoints. Cell cycle checkpoints monitor progression of cell cycle and can 
sense DNA damage through interacting pathways. There are 3 main checkpoints 
in cell cycle: G1/S transition, S stage progression and G2/M transition. Upon DNA 
damage or failure of previous activity in cell cycle, these check points interrupt cell 
cycle to provide time for repair DNA damage. This leads to delayed cell cycle 
progression or cell cycle arrest (152,153). 
 In recent years, many studies with the circadian clock genes mutations 
have demonstrated the connection between the circadian clock and the cell cycle. 
In unicellular organisms, restriction of DNA synthesis to nighttime for protection 
from UV damage suggested a possible control of cell cycle by the circadian clock 
(154). Studies with microarray analysis and measurement of cell cycle genes 
expression have reported potential targets for this regulation at various stages of 
cell cycle. Some of them are discussed below.  
The transcription factor c-myc is important regulator of G1 stage. Reporter assay 
studies demonstrated that c-myc is a clock controlled -gene. The bmal1/NPAS2 
(clock homolog) complex transcriptionally repress c-myc promoter (154). One of 
the important target gene of c-myc is Gadd45α which is involved in cell growth 
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arrest. Gadd45α is negatively regulated by c-myc. Therefore, disruption of the 
circadian clock can result in upregulation of c-myc and thereby downregulation of 
Gadd45α resulting in continuous cell cycle progression (155,156). The 
BMAL1/CLOCK complex also directly regulates expression of Wee 1 kinase that 
regulates G2-M transition. Wee1 kinase inactivates the cdc2/cyclin B1 complex by 
phosphorylation. It results in cell cycle arrest at G2-M interface. Wee1 Kinase is 
also activated in response to DNA damage (157). Additional many cell cycle genes 
involved in G1-S and G2-M regulation such as Cyclin B1, Cyclin D1, Cyclin D3, 
cdk4 have E boxes in their promoters that are recognized by BMAL1/CLOCK 
complex and show circadian oscillations in their expression (155,158).P21 is a 
cyclin-dependent kinase inhibitor that interacts with cdk2 complexes to regulate 
progression through G1. Bmal1 deficiency was reported to up regulate expression 
of p21 in liver. Although no BMAL1/CLOCK responsive elements have been 
identified in the promoter region have been identified in the promoter region of p21, 
it might be indirectly regulated by BMAL1/CLOCK complex via RORs and REV-
ERBs nuclear receptors (159,160). 
Other groups have also demonstrated link between the clock proteins 
PERIODs and TIMELESS with cell cycle check point kinases ATM (Ataxia 
telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related protein). 
In response to DNA double strand breaks, ATM activates CHK2. Activated CHK2 
inhibits activation of cdc2 required for cell cycle progression by inhibiting cdc25 
phosphatase by phosphorylation. It was shown that PERIOD1 can interact with 
ATM/CHK2 complex and this interaction is important for activation of CHK2.  Also, 
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TIM interacts with ATR/ATRIP (ATR interacting protein) and CHK1 kinase in 
response to stalled replication forks for G2/M arrest and the interaction is critical 
for CHK1 activation (161,162,163). 
Based on our observations of increased proliferation of immortalized 
Bmal1-/- fibroblasts we hypothesized that Bmal1 deficiency can result in 
deregulation of clock controlled cell cycle regulators that can result in change in 
progression though cell cycle for Bmal1-/- cells.To test this hypothesis we propose 
following experiments. We will perform cell cycle analysis of WT and Bmal1-/- 
immortalized lung fibroblasts using flow cytometry. This analysis will indicate 
relative number of cells in G1, S, G2 and M stage of cell cycle. The stage with least 
number of cells is likely the stage affected by Bmal1 deficiency. Depending on the 
number of cells per stage, we can assess expression of cell cycle regulators at 
mRNA level by Quantitative PCR and protein level by western blotting.  
During our experiments, we also observed that Bmal1 deficiency results in 
reduced sensitivity to certain anticancer drugs such as Etoposide and 
Daunorubicin. Based on our observations, we can hypothesize that the reduced 
sensitivity to Etoposide and Daunorubicin can be due to deregulation of cell cycle 
check points, we can perform cell cycle analysis. WT and Bmal1-/- cells treated 
with Etoposide and Daunorubicin can be analyzed for cell cycle distribution. The 
Bmal1-/- cells demonstrating higher number of cells in specific stage compared 
with WT suggests regulation by BMAL1.   
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4.2 Conclusions 
Even after extensive work in the field of aging, mechanisms are poorly 
understood. Many studies with mutations of mTORC1 pathway components that 
either inhibit mTORC1 activity itself or its downstream effects have shown that 
inhibition of mTORC1 extends lifespan in various models from flies to mice. 
Treatment with Rapamycin (mTOR inhibitor) or calorie restriction (can affect 
mTORC1 activity) have been shown to extend life span in mice. This indicates that 
mTORC1 plays a significant role in aging.  
Our results show that the circadian clock regulates mTORC1 activity 
through BMAL1 dependent mechanism and that increased mTORC1 activity can 
contribute to premature aging and age related pathologies in Bmal1-/- mice. Our 
findings suggest importance of appropriate function of circadian clock in 
organism’s well-being and in aging with the fact that, we revealed two different 
ways (oxidative stress induced senescence and regulation of mTORC1 activity) 
through, which Clock is connected to aging. The research presented in this 
dissertation also indicates a vast unexplored area of mechanisms through that 
circadian clock is involved in aging. 
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